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ABSTRACT 
Systematic constancy and accuracy of a treatment planning system (TPS) are 
crucial for the entire radiation treatment planning process (TPP).  The Quality Assurance 
(QA) of individual components does not necessarily lead to satisfying performance of the 
whole process due to the possible errors introduced by the data transfer process between 
components and other fluctuations.  However, most of current QA for TPS is confined to 
the treatment planning computers.  In this study, a time efficient and integrated CT-TPS 
QA procedure is presented, which starts at the beginning of the TPS input --- Computer 
Tomograhpy (CT).  The whole QA procedure is based on the concept of simulating a real 
patient treatment.  Following the CT scan of a head phantom with geometrical objects, a 
set of reference treatment plans for each accelerator, with all energy beams included, 
were established.  Whenever TPS QA is necessary, the same procedure is repeated and a 
QA plan is produced.  Through the comparison of QA plan with the reference plan, major 
systematic errors can be found easily and quickly.  This method was also applied to 
VariSeed and PLATO Brachytherapy treatment planning systems. 
Moreover, if any error is detected in the system, TPS is broken into several parts 
and individual tests are also set up. 
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CHAPTER 1. INTRODUCATION 
1.1 Treatment Planning Process  
The treatment planning process usually involves beam data representation, patient 
data acquisition, definition of treatment portals, dose calculations, dose display, dose 
evaluation, and finally the plan documentation (Fraass et al. 1996) 
First, the patient positioning and immobilization is set up.  These position and 
immobilization methods are going to be used when real treatment is ongoing. 
Following that, the patient data is registered by Computed Tomography (CT).  
Typically, CT images are acquired at transverse planes with a separation of 1 to 10 mm.  
Based on these images, the physician can estimate the size, extent, and location of the 
tumor.  Sometimes, magnetic resonance imaging (MRI) and positron emission tomogrphy 
(PET) are used to set up a more accurate patient model and particularly to improve the 
accuracy of the tumor location.    In some cases, the treatment fields and technique are 
determined during the image acquisition. 
The next step is treatment planning using a computer system.  Treatment planning 
computers get patient image data from the image acquisition equipments.  Physicians and 
dosimetrists delineate normal anatomic structures and the target volumes; add the beam 
and beam modifiers; give the prescription and calculate the dose.  After the plan 
evaluation and approval by medical physicists and radiation oncologists, the treatment 
plan is printed out as a hardcopy for patient treatment and records.  The final plan is also 
sent to the verify and record system (e.g. IMPAC) for patient treatment. 
Finally, the plan is verified by additional radiographic imaging (e.g. port films) 
before the dose is delivered to the patient. 
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The whole process of the radiation therapy process can be illustrated in the 
following flowchart: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Flowchart of radiation treatment process 
 
Uncertainties or errors in any step of this process can have a significant effect on 
the outcome.   
1.2 Treatment Planning System 
Basically, a treatment planning system (TPS) includes a computer workstation 
and input and output devices for graphics and images.  Further complex components of a 
3D TPS are the dose calculation algorithm code and the program used to manipulate 3D 
graphic displays of the patient, the beam geometry, and the dose.   
1.3 Acceptance Test of TPS 
An acceptance test is carried out to find out whether the TPS system performs 
according to the manufacturer’s specifications.  The objective is to know how the TPS 
should perform in various situations. 
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1.4 Commissioning of TPS 
Haken (1996) divided commissioning of a TPS into two parts, the nondosimetric 
commissioning and dosimetric commissioning.  Nondosimetric commissioning is used to 
handle the TPS functions not directly related to the dose calculation.  It is mainly TPS 
dependent, and usually includes image acquisition, anatomical description, and beam 
description.  Dosimetric commissioning validates the dose calculation of a TPS.  It 
contains measured beam data input, defining dose calculation algorithm parameters and 
verification of the calculation.  
1.5 Quality Assurance (QA) 
According to the definition of International Standards Organization (ISO), quality 
assurance (QA) means all the planned or systematic actions necessary to provide 
adequate confidence that a product or service will satisfy given requirements for quality. 
Specifically in radiation oncology, the quality can be defined as the totality of 
features or characteristics of the radiation oncology service that bear on its ability to 
satisfy the stated or implied goal of effective patient care (G. Kutcher et al. 1994).  QA of 
radiation therapy equipment is primarily an ongoing evaluation of functional performance 
characteristics. Quality assurance is essential to the safe and effective treatment of 
patients, the analysis of data, and the design of prospective research. 
1.6 Why TPS QA 
In the entire radiation treatment process, the treatment-planning computer is a 
crucial component, as it covers a wide range of applications.  Since they are related to the 
control of the disease or to complications as a result of inappropriate treatment, all of 
these planned or systematic actions must be ensured working properly.  Unlike treatment 
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delivery errors, which are usually random in nature, the errors from treatment planning 
systems are more often systematic and constant for all the patient treatments.  Also, no 
system of computer programs is perfect, nor are the users of such programs error free. 
The treatment planning computers are subject to electronic and mechanical failure. 
With the rapid evolution of treatment planning systems, QA for treatment-
planning computers has lagged behind, especially after the introduction of 3-D treatment 
planning system and the dynamic wedge.  Medical physicists are challenged to ensure 
that innovations in TPS and delivery systems meet agreed-upon standards for quality 
assurance.  The lack of proper TPS QA procedures has led to some serious accidents.  An 
example of the consequences of inadequate TPS QA is as follows. 
In May 25, 2001, the International Atomic Energy Agency (IAEA) sent a team of 
six international experts to assist the authorities of Panama to deal with the aftermath of a 
radiological accident that occurred at Panama’s National Oncology Institute.  In this case, 
it was possible to enter data in one batch for several shielding blocks in different ways. 
For some of these ways of entering the data, the output values were calculated 
incorrectly.  The consequence is that five patients died and the team confirmed that these 
deaths were attributable to the patients' overexposure to radiation.  Of the surviving 20 
patients, about three-quarters of them developed serious complications, which in some 
cases may ultimately prove fatal. 
Also, TPS quality assurance is required by the American College of Radiology 
(ACR).  To be an ACR accredited institution, the TPS QA procedure must be setup and 
performed regularly. 
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1.7 QA at Mary Bird Perkins Cancer Center (MBPCC) 
At MBPCC, QA procedures for the treatment planning system have also fallen 
behind.  A 3-D treatment planning system was brought into MBPCC about 2 years ago, 
but no quality assurance program has ever been set up or performed for Theraplan or 
Pinnacle3.  At the same time, TPS is used every day for almost all of our patients.  If there 
is any minor error, the cost would be unpredictable.  With this motivation, a systematic 
update of the QA procedure is required. 
1.8 Summary 
Treatment Planning System (TPS) QA is a vital requirement, even though 
MBPCC is not as big as some huge cancer centers and has limited medical physicist 
staffs.  As TG-53 says, the quality assurance requirements in a small radiation oncology 
facility should be no less than those in a large, academic medical center.   
In this study, focus would be put on the Pinnacle3 external beam treatment 
planning system QA. 
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CHAPTER 2. LITERATURE REVIEW 
As for the significance of TPS, there are plenty of references available regarding 
TPS Quality Assurance.  To guide and help medical physicists in developing and 
implementing a comprehensive but realizable program of quality assurance in treatment 
planning system, the American Association of Physicists in Medicine (AAPM) organized 
a Task Group 40 to summarize the essential points found in these literature.  Later, due to 
the importance and increasing sophistication and complexity of treatment planning 
systems, the American Association of Physicists in Medicine (AAPM) Task Group report 
53 was issued in 1998.  
2.1 The TG-40 
The TG-40 report (Comprehensive QA for Radiation Oncology) was published in 
1994, when most institutions were still using 2-D treatment planning systems.  Therefore, 
this report is special for the 2-D treatment planning computers.  Some of the 
recommendations are already obsolete.  However, it provides a basic idea about what to 
check and how often it should be checked.  The recommendations for the ongoing TPS 
QA by the TG-40 report are shown in Table 2.1. 
This report also points out that QA of treatment-planning systems is an evolving 
subject.  It keeps changing, and physicists need to keep up with the improvements. 
2.2 The TG-53 
In TG-53 (Quality Assurance for Clinical Radiotherapy Treatment Planning), 
routine QA is also emphasized as being a very important part of the TPS QA program 
after an initial commissioning of the dataset.  According to the AAPM TG-53 report, the 
main aims of a routine periodic QA program for RTP system include the following. 
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Table 2.1 TG-40 recommendations on the frequency of treatment planning 
computers QA 
Frequency Test Tolerance 
Understand algorithm Functional 
Single field or source 
isodose distribution 
 
2% or 2 mm 
MU calculation 2% 
Test cases 2% or 2 mm 
 
 
Commissioning and 
following software update 
I/O system 1 mm 
Daily I/O devices 1 mm 
Checksum No change 
Subset of reference QA test 
set (when checksum not 
available) 
 
2% or 2mm 
 
 
Monthly 
I/O system 1 mm 
MU calculation 2% 
Reference QA test set 2% or 2 mm 
 
Annual 
I/O system 1 mm 
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First, the calculation algorithms of the TPS need to be tested periodically, relative 
to the accuracy, precision, and limitations of the algorithm, as well as the implementation 
of the software for isodose planning calculation and display.  Most physicists may 
understand the algorithm very well, but may not be aware of the software weaknesses.  
After many years’ development, the algorithm tends to improve; therefore, although this 
is still an important test, it is not as critical as it was previously. 
Secondly, the correct functioning and accuracy of peripheral devices used for data 
input need to be verified.  These include the digitizer tablet, CT, MRI, video digitizer, 
simulator control system, and devices to obtain mechanical simulator contours.  One must 
separately consider the devices themselves and the networks, tape drives, software, 
transfer programs, and other components, which are involved in the information transfer 
from the device to the TPS system. 
The third objective is to confirm the integrity and security of the TPS data files 
that contain the external beam and brachytherapy information used in dose and monitor 
unit calculations. 
Finally, it is necessary to confirm the function and accuracy of output devices and 
software, including printers, plotters, automated transfer processes, connections to 
computer-controlled block cutters and/or compensator makers, etc. 
2.3 Lecture by Van Dyke in 2001 AAPM Annual Meeting 
The latest report on TPS QA was given by Van Dyke in the 2001 AAPM annual 
meeting.  In this lecture, Van Dyke proposed the following items be checked after the 
acceptance test and commissioning of TPS. 
• Program and system documentation 
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• User training 
• Sources of uncertainties 
• Suggested tolerances 
• Initial system checks (recommissioning) 
• QC – repeated system checks 
• QC – patient specific monitor unit checks 
• QC – in vitro/vivo dosimetry 
• QA – administration 
Van Dyke also mentioned some challenges in QA testing.  For example, is the 3-
D image information acquired and transferred accurately from the imaging device to the 
treatment-planning computer?  Does the treatment planning software provide accurate 
reconstruction of the data provided by the imager? 
2.4 Documentation Requirement 
Documentation is an important part of the Quality Assurance procedure, but is 
easy to be ignored.  Dahlin et al. (1983) have proposed some basic documentation 
requirements that should be available to the TPS user: 
1. System description giving the general concepts of the system and the 
hardware/software structure. 
2. User’s guide giving a clear description for overall system usage. 
3. Data file formats including a description of file contents. 
4. Text file descriptions of communication files and how the user might edit such 
files for local use. 
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5. Algorithm descriptions, which include a clear indication of the physical models 
with all the relevant mathematical relationships and the corresponding levels of 
accuracy.  The system capabilities and program limitations should be clearly 
outlined, preferably with an up-to-date list of scientific references.  A detailed 
description of dose normalization procedures should be included. 
6. Device handlers must be described in the form of available libraries to ensure the 
user access to available hardware peripherals. 
7. Access to necessary software libraries including programmer handbooks for local 
programming. 
8. Basic data description of necessary basic data and how it is entered into the 
system. 
2.5 Other Works 
Bruce Curran et al. (1991) suggested checking treatment-planning computers 
using a reference plan, but their tests were limited to checking the computer itself.  They 
separately tested the input, treatment computers, and output devices.  This made the QA 
procedure extremely complex.  Although they have simplified some individual test 
procedures, the whole process was still too complicated.  
2.6 Summary 
Although the American Association of Physicists in Medicine (AAPM) has 
published the TG-40 and TG-53 reports to guide physicists in performing treatment 
planning system QA, both reports only give a framework.  Neither describes details about 
how to perform the TPS QA step-by-step.  Moreover, TPS QA is a complicated task.  It is 
different from one clinic to another, since every clinic has its own special situations, e.g. 
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different treatment planning computers (TPC) and different facilities.  As most medical 
physicists have noticed, it is impossible and unrealistic to build a single set of procedures 
and apply them to all situations.  TPS QA procedures must be established based on each 
institution’s own special situation. 
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CHAPTER 3. GLOBAL METHODOLOGY 
3.1 Procedure 
QA of treatment planning system is a comprehensive and systematic procedure 
that involves consistency verification throughout the planning process from initial 
localization on through to the output of treatment planning.  Besides the establishment of 
QA procedures, there are two points that need to be clear.   
First, the input of external beam TPS is the CT-Simulator.  Almost all of the 
patient images are obtained from the CT-Simulator.  It does not make sense only to check 
the external beam TPS accuracy without the CT-Simulator working correctly.  The 
connection between the CT-Simulator and external beam TPS is DICOM (digital image 
communication in medicine), which transfers the image series.  This image transfer is 
also an important part of the treatment planning process.  Therefore, the TPS has to be 
checked with the CT-simulator as a system. 
Secondly, the TPS QA is an extremely time consuming and labor extensive work.  
If all aspects of the TPS were checked, it would take more than one full time medical 
physicist to complete it.  In reality, it is costly and unnecessary.  As recommended by the 
AAPM TG-53 report, only selected points with possible errors need to be checked 
routinely.  Design of an appropriate QA program depends strongly on the planning 
system capabilities and how these capabilities will be used clinically.  It is extremely 
important to incorporate the limitations of the planning system and its intended use 
directly into the design of the QA procedures. 
Because of the reasons above, we set up a procedure to test CT-TPS integration, 
which is one of the points making our work different from others.  Our integration QA 
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examines the systematic errors.  After checking the integrity, the question is what should 
be done if there is any error in the CT-TPS integration QA.  Our way is to break the 
integration and check ADAC and CT individually. 
For the VariSeed 6.7 planning system and the PLATO Brachytherapy HDR 
planning system, a similar method is used for the QA procedures.  Some reference plans 
were established to verify the systematic process accuracy.  If any errors were found in 
the QA, individual tests will be performed to check the devices separately. 
3.2 Schedule 
The schedule of the routine QA tests largely depends on the kinds of issues being 
monitored.  We need to know how often the feature is used in clinical procedures and 
how critical this feature is.  The TG-40 report gives a recommendation on the frequency 
of routine QA.  Our schedule will be based on that recommendation and the situation at 
our institution. 
3.3 Criteria for Acceptability 
The International Commission of Radiation Units and Measurements (ICRU, 
1978) have specified a tolerance of 2% in relative dose accuracy in low dose gradients or 
2 mm spatial accuracy in regions with high dose gradients.  For brachytherapy, the aim is 
3% accuracy in dose at a distance of 0.5 cm or more, at any point for any radiation 
source.  However from the experience of many other cancer centers (Starkschall et al. 
1998), this is an unrealistic goal, in spite of the extensive effort of developers for new or 
improved dose calculation algorithms.  Right now, the most popular criteria are proposed 
by J. Van Dyk (1991) and widely accepted by most of medical physicists (Table 3.1). 
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Table 3.1 Dose calculation criteria recommended by J. Van Dyk 
Beam Photon Electron 
Density Distribution Homogeneous Heterogeneous Homogeneous Heterogeneous
Central ray data 2% 3% 2% 5% 
High dose, low 
gradient 
3% 4% 4% 7% 
Hi gradient 4mm 4mm 4mm 5mm 
Low dose, low 
gradient 
3% 3% 4% 5% 
 
In our QA test, it checks the reproducibility of the whole TPS, which is different 
from the comparison between calculation and measurement.  It is less strict because the 
treatment planning system has more reliability and constancy.  However, it is useless to 
have an extremely small criterion because the error in the radiation treatment process 
(RTP) is an accumulated error.  If other parts of the treatment planning process introduce 
greater errors, the whole RTP error would be still high.  We have set our own criteria in 
reference to the tolerance of dose calculation and the results obtained in our QA tests. 
3.4 Software Upgrade 
One of the most difficult parts of designing QA for TPS is to establish a 
reasonable QA program for software upgrades.  The full commissioning of a 3-D 
treatment planning system may take up to several months or even longer; therefore it is 
obviously not practical to perform such a full commissioning test on each new version of 
the software.  However, at the same time, it is well known that changes in the software 
can lead to unintended and undesirable consequences in function and data.  Old bugs may 
be fixed, but new bugs may have been introduced.  Testing must be performed to check 
the accuracy. 
The first thing for medical physicists to do after a software upgrade is to 
understand what has been changed compared to the older version software.  This needs to 
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be coordinated with the software manufacturer.  Usually, the vendor of the software 
provides a list of changes and new features in the software.  The new features should be 
tested and results should be documented. 
In this study, the same ongoing TPS QA test procedures are also used to test the 
software upgrade, but the test order is reversed.  First, make a software individual test 
without CT scan so as to check the changes of the treatment planning computers, instead 
of the whole treatment process.  If there were no significant change in the dose 
calculation algorithm, the same result would be obtained.  After that, the integrated QA 
process can be used to assure that there is no change in the whole treatment planning 
system. 
3.5 Summary 
The TPS-CT integrated test will be used for TPS QA by simulating the actual 
patient treatment process.  Also, TPS and TPS input individual QA will also be 
established to check individual parts of the system when any error is found in the 
integration test results.  All of the tests are designed based on MBPCC specific situations. 
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CHAPTER 4. CT- PINNACLE3 QA 
4.1 Introduction 
4.1.1 What is Pinnacle3 
Pinnacle3 is the external beam treatment planning system utilized at MBPCC, 
which is provided by Philips ADAC Laboratories.  The ADAC Pinnacle3 RTP system 
runs on a Sun UNIX workstation with a Solaris operating system.  The software supports 
radiation therapy treatment planning for treatment of benign or malignant diseases. 
4.1.2 Pinnacle3 Algorithms 
4.1.2.1 Algorithm of Photon Beam Physics  
Pinnacle3 uses the Collapsed Cone Convolution Superposition dose algorithm, 
based on the work of Mackie, et al., 1985.  The Collapsed Cone Convolution 
Superposition dose model consists of three parts. 
• Modeling the incident energy fluence as it exits the accelerators head. 
• Projection of this incident energy fluence through the density representation of a 
patient to compute a TERMA (Total Energy Released per unit Mass) volume. 
• A three-dimensional superposition of the TERMA with an energy deposition 
kernel to compute dose.  A ray-tracing technique is also used during the 
superposition to incorporate the effects of heterogeneities on lateral scatter. 
The Pinnacle3 photon beam model parameters characterize the radiation exiting 
the head of the linear accelerator by the starting point of a uniform plane of energy 
fluence describing the intensity of the radiation.  Then Pinnacle3 adjusts the fluence 
model to account for the flattening filter, the collimators, and beam modifiers such as 
blocks, wedges, and compensators. 
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4.1.2.2 Algorithms of Electron Physics 
The Pinnacle3 electron dose calculation uses the Hogstrom pencil-beam algorithm 
(Hogstrom et al. 1982).  The algorithm uses a combination of measured data and model 
parameters that characterize the electron beam physics.  After determining the 
appropriate electron model parameters, dose lookup tables are generated to use for dose 
calculation. 
4.1.2.3 Algorithm Accuracy 
As recommended by TG-53 and other literature, the treatment planning system 
algorithm needs to be tested.  However, verifying the accuracy of the dose computation 
requires a comprehensive set of test cases.  The tests should include a lot of special 
geometry cases, such as oblique incidence of the radiation beam (e.g. tangential breast 
irradiation) or multiple density heterogeneities.  Dose distributions can generally be 
calculated very well for a radiation beam at normal incidence on a water phantom but 
their accuracy in a variety of clinical situations is questionable. 
The American Association of Physicists in Medicine (AAPM) Radiation Therapy 
Committee Task Group 23 (TG-23) developed a test package for verifying the accuracy 
of photon-beam dose-calculation algorithms.  Data for the test cases were acquired for 
two beam energies from two Clinical linear accelerators: a 4-MV x-ray beam from a 
Clinna-4 (Varian Oncology Systems, Palo Alto, CA), and an 18-MV x-ray beam from a 
Therac-20 (Atomic Energy of Canada, Ltd., Kanata, Ontario, Canada).  However, it is a 
time consuming and labor intensive job to complete all of these test cases. 
Fortunately, with the help of Philips ADAC laboratory, M.D. Anderson Cancer 
Center developed a more extensive set of measured data to verify the accuracy of the 
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photon dose-algorithm in Pinnacle3, which is the same treatment planning system used at 
MBPCC (Starkschall et al. 1998).  Their results show that the Pinnacle3 treatment 
planning system calculated photon doses to within the American Association of 
Physicists in Medicine (AAPM) Task Group 53 (TG-53) criteria for 99% of points in 
buildup region and 90% of points in the penumbra.  For the heterogeneous phantoms, 
calculations agreed with actual measurements to within +/-3%.  The monitor unit tests 
revealed that the 18-MV open square fields, oblique incidence, oblique incidence with 
wedge, and mantle field test cases did not meet the TG-53 criteria but were within +/-
2.5% of measurements. 
The algorithm tests above required a whole team to complete the work at 
considerable expense.  It is impractical and unnecessary to repeat these test cases.  In this 
study, we utilize M. D. Anderson Cancer Center’s results and do not make further tests 
on our own Pinnacle3 planning system.   
4.2 Methodology 
In this study, two methods were used to check the Pinnacle3 constancy and 
accuracy. 
4.2.1 Check Sum Program 
Firstly, the “sum” program in the Unix system was used.  This program calculates 
and prints a 16-bit checksum signature for the named file, and also prints the number of 
blocks in the file.  It is typically used to look for bad spots or to validate a file 
communication over transmission lines.  Initially, all of the machines’ database files were 
checked by the “sum” program and all the signatures (results) were stored as reference.  
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In the QA process, some of the files are selected and the signatures are spot-checked.  
The result should be exactly the same as the reference plan. 
One requirement for the use of checksum program is to follow the changes made 
to the machine data.  If the checksum result is different from the reference, we should be 
able to find out the reason for the changes. 
4.2.2 Reference Cases 
Secondly, a series of reference plans starting from CT and ending up with 
Pinnacle3 dose calculation were established.  The whole QA process simulates the actual 
patient treatment planning process. Detailed steps are as follows. 
4.2.2.1 CT Scan of a Radiosurgery Heterogeneous Head Phantom 
A radiosurgery heterogeneous head phantom was scanned by a CT scanner using 
the most typical head scan technique parameters (See table 4.1).   The phantom is 
connected to the CT couch by a radiosurgery head phantom holder, as shown in Figure 
4.1.  After the first scan, a CT scan protocol was set up.  The protocol bypasses the step 
of image scouts, ensuring that the exact same scan technique is used each time.  This also 
reduces the total scanning time.  
Table 4.1 Pinnacle3 QA Phantom CT-scan parameters 
Scan method KV mA Time Thickness Gantry Ang Total Slices
Helical 140 150 72 sec 3mm 0.0 48 
 
Three B. B markers were put on the phantom aligning with the CT internal laser 
in order to find out the same relative position in the image series scanned at different 
times.  Later, if the dose distribution needs to be measured in LINACS, B. B. markers can 
also be used to align the LINACS lasers and find the isocenter point. 
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4.2.2.2 Transferring of Image Series to Pinnacle3 
Within the CT computer network, the image series were sent to Pinnacle3 by 
DICOM (Digital Image Communication in Medicine), which is widely considered as one 
of the possible resources contributing to errors.  Our QA test can catch this kind of errors 
because the phantom images also go through this step.  Were there any errors, it would 
show up in the final treatment plan comparison. 
 
Figure 4.1 QA phantom connected to CT couch 
4.2.2.3 Saving Image Series as a Pinnacle3 Phantom 
After importing the image series to the Pinnacle3, a new treatment plan was added 
with the imported image series as the primary CT image series.  In this new plan setup, 
the laser point is defined as the point aligning with the B. B. markers.  This is a very 
important because all of the coordinates should be relative to the laser point in order to 
keep all contours and POI in the same relatively positions.  After exiting the treatment 
planning, this plan was saved as a Pinnacle3 phantom named “QA HEAD PHANTOM”. 
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4.2.2.4 Transferring an Actual Patient Plan Technique 
Different plans were devised for different machines. 
For the 21EX(Baton Rouge) and 21EX(Covington), they have Multiple Leaves 
Collimator (MLC) and Intensity Modulation Radiation Treatment (IMRT) can be applied.  
Thus an actual head tumor patient IMRT treatment plan with 6 beams (256 Brain, 180 
Brain, 95 Brain, LSO Brain, VERTEX Brain, and RSO Brain) was selected and copied to 
the “QA HEAD PHANTOM”.  Some new contours and points of interest (POI) were 
added.  The contours included critical organs in order to check the DVH calculation.  
Most of POIs are around the tumor or in the high gradient dose region.  If either the 
image position or computer calculations have errors, the dose change would be relatively 
larger and more easily observed. 
For the other three machines (2100C, 600C and 2000CR), an actual patient 3-D 
conformal head tumor treatment plan was transferred to the “QA HEAD PHANTOM”.  
This plan included blocks, wedges and boost beams, which allow us to test all of these 
characteristics.  After transferring, some contours and POIs were also added to the plan. 
There are two advantages to transfer the treatment plan technique.  First, a whole 
treatment plan technique can be transferred to “QA HEAD PHANTOM”, resulting in no 
need to add all the beams, plot blocks, contour organs, defined POI, and so on.  This 
saves a huge amount of time and it is one of the reasons that the TPS QA in this study can 
be completed much more quickly than other work.  Secondly, all of the treatment 
parameters can be kept the same.  Without transferring, many parameters, like the block 
shape, calculation grids and contour shapes are very difficult or even impossible to be 
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kept in the exactly same.  The treatment plan transferring is the key of all of our TPS QA 
procedures. 
4.2.2.5 Dose Calculation and Printout 
The dose distribution was calculated with the Adaptive Convolve Method, which 
is the most common method used by dosimetriests.  Following that, the treatment plan 
report, DVH, DRR, three 2-D isocenter plane images and isodose distribution for every 
three slices were all printed out.  All of these printouts are in keeping with how 
dosimetrists typically operate and provided as a treatment plan to physicians.  The correct 
printout shows us the TPS output devices are working properly.   
4.2.3 QA Plan Making 
Whenever a TPS QA is necessary, we will repeat the generation of the reference 
plan and make a QA plan.  Then the QA plan result was compared to the reference plan 
result.  If the Pinnacle3 and CT integration TPS has been working consistently, the QA 
plan result should be the same or only slightly different from the reference plan.  A QA 
treatment plan is generated in manner very similar to the reference plan---scan the 
phantom in the same position, transfer the images, save them also as “QA HEAD 
PHANTOM”, and calculate the dose distribution.  But there are also some differences as 
follows. 
First, transfer the reference plan instead of actual patient plan to the QA plan.  In 
this way, the QA plan can be initialized with all of the beams, contours, points, 
prescriptions, blocks, wedges and grids already included in the reference plan. 
Secondly, the alignment point of transferring the reference plan should be the new 
ISO at the new phantom image series.  To find the coordinates of the new ISO, it is 
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necessary to compare the differences between the new laser coordinate and the reference 
plan laser coordinate.  The sum of the laser coordinate difference with the reference plan 
ISO coordinate would be the new ISO coordinate.  For example, suppose the new laser, 
the reference plan laser, and the old ISO coordinates are (-0.41, 0.03, 0), (-0.20,0.05,0) 
and (-5.00, 0.53, 3.00) respectively.  The laser coordinate difference is (-0.21, -0.02, 0).  
Thus the new ISO coordinate is (-5.00, 0.53, 3.00) + (-0.21, -0.02, 0) = (-5.21, 0.51, 
3.00).  All beams, contours and POI coordinates need to be adjusted by the laser 
coordinate difference so that they had the same relative location to the ISO point as 
before. 
It should be noted that all the tests for all of the machines do not need to be done 
at the same time.  Performing the reproducibility tests for different machines at different 
times reduces the time required in ongoing TPS QA. 
4.2.4 Comparison 
It is always hard to compare two treatment plans quantitatively.  In this study, 
point dose, monitor unit per fraction, dose profile, DVH and isodose lines were used for 
comparison. 
4.2.4.1 Point Dose 
When designing the reference plan, four points in the high gradient region and 
four points in the low gradient region were added.  Pinnacle3 gives us a detailed report 
about the dose contribution from each beams as well as the total dose, which is very good 
for quantitative comparisons.   
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4.2.4.2 Monitor Unit per Fraction for Each Beam 
The Pinnacle3 plan report also provides all the information about the calculation 
of monitor unit.  By comparing the monitor unit, Normalized Dose (ND) at reference 
point, collimator output factor, tray/block & tray factor, total transmission factor, and 
MLC transmission factor can be tracked.  If physicists changed any of these factors, it 
can be verified by our QA test easily. 
4.2.4.2 Dose Profile 
Dose profile between any two defined points was calculated and it is illustrated in 
Figure 4.2.  By putting the new profile and reference plan profile together on a view box, 
any big difference can be found. 
4.2.4.3 Dose Volume Histogram (DVH) 
 
 
 
 
 
 
 
 
 
Figure 4.2 Example of dose profile in the output of ADAC 
 
Dose volume histograms (DVH) are graphic representations that relate the dose 
received by the patient and the volume of tissue receiving each dose.  It can be used to 
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summarize 3-D dose distribution in tumor and normal tissue volumes, which makes it a 
powerful tool for quantitative evaluation of a 3-D treatment plan.  The grid spacing and 
size assignment of voxel to the structure and the binning affect the accuracy of DVH 
(Kessler et al 1994).  In our test, the grid spacing and the size assignment of voxel to the 
structure and the binning are always kept the same because of the whole plan transfer.  
The QA plan is expected to get the same DVH as the reference plan. 
The quick and easy way to see the DVH comparison is to put the DVH printout 
with the reference DVH together on a view box to see if they overlap each other.  Figure 
4.3 is an example of DVH provided by Pinnacle3. 
 
 
 
 
 
 
 
 
 
Figure 4.3 Example of DVH provided by Pinnacle3 
 
The comparison can also be performed quantitatively through the DVH data table 
(Table 4.2).  50%, 25%, 5% and 2% dose point coordinates were compared. 
For example, in Table 4.2, it can be seen that the volume of this organ_2 in the 
21EX(BR) reference plan is 2.33cc.  50% volume would be 2.33 x 50% = 1.17cc.  From  
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Table 4.2 DVH data table for organ_2 in 21EX(BR) reference plan 
Read across columns and down rows. 
cGy/cc 0.0 26.8 53.5 80.3 107.0 133.8 160.5 187.3 214.0 240.8 
0.0 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 
267.6 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.32 2.30 2.26 
535.1 2.24 2.21 2.18 2.15 2.13 2.10 2.07 2.04 2.00 1.97 
802.7 1.94 1.90 1.87 1.84 1.80 1.77 1.73 1.71 1.68 1.65 
1070.2 1.63 1.60 1.58 1.56 1.54 1.52 1.51 1.49 1.48 1.46 
1337.8 1.44 1.44 1.42 1.41 1.40 1.39 1.38 1.37 1.36 1.35 
1605.3 1.33 1.32 1.31 1.30 1.29 1.28 1.27 1.26 1.25 1.23 
1872.9 1.22 1.21 1.20 1.19 1.18 1.16 1.15 1.13 1.12 1.10 
2140.4 1.09 1.07 1.05 1.03 1.01 0.99 0.98 0.95 0.93 0.91 
2408.0 0.89 0.87 0.85 0.82 0.80 0.78 0.76 0.74 0.72 0.70 
2675.5 0.69 0.66 0.64 0.63 0.61 0.59 0.57 0.55 0.54 0.52 
2943.1 0.51 0.49 0.47 0.46 0.45 0.43 0.42 0.40 0.39 0.37 
3210.6 0.36 0.35 0.33 0.32 0.31 0.30 0.29 0.27 0.26 0.25 
3478.2 0.24 0.23 0.22 0.21 0.20 0.18 0.18 0.17 0.16 0.15 
3745.7 0.14 0.13 0.12 0.12 0.11 0.10 0.10 0.09 0.08 0.07 
4013.3 0.06 0.06 0.05 0.04 0.04 0.04 0.03 0.02 0.01 0.01 
4280.9 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4548.4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
4816.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
5083.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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the table, 1.17 cc is responding to ninth row (1872.9cGy) and between 6th (+ 107.0cGy) 
and 7th (+133.8cGy) column.  So in the QA plan, 50% volume dose for this contour 
should also respond to a close coordinate, which means the row number should be the 
same and the column number should only be off one position at most. 
4.2.4.4 Isodose Line 
The most common method to display measured and computed dose distributions 
is isodose lines.  For instance, the physician defines 100%, 98% or 97% isodose lines as a 
prescription.  These contours are generated by searching a dose array for the pixels at a 
particular dose level and creating a plotline, which passes through those pixels.  In our 
reference plan, 50.0%, 80%, 90%, 95% and 100% isodose lines were included in the 
printout.  The printout can also be overlaid with the reference plan printout on a view 
box.  If the shape or position of these lines changes, they are obviously displayed. 
4.2.4.5 Digitally Reconstructed Radiograph (DRR) 
DRR are images analogous to conventional simulation films.  The four main 
parameters affecting DRR construction are slice thickness, VOI, Window Width and 
level, and Contrast / Brightness (McGee 2000).  Since Digital Reconstructed Radiographs 
are used as a standard of comparison for portal placement, the geometric accuracy of the 
anatomical data represented must be verified.  In Pinnacle3, DRR can be printed out on 
both paper and films.  Both were compared to the reference plan. 
4.2.4.6 Printout Accuracy 
The input image and the printout are supposed to be consistent with each other.  
Printout uncertainties could lead to improper selection of treatment plans that do not 
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adequately cover the target volume.  The radiosurgery QA phantom dimensions were 
measured by a caliper, and compared to the measurement on the output of the plotter. 
4.2.5 Digitizer QA in Pinnacle3 
All of the input images are taken from CT-Simulator instead of digitizer for 3-D 
treatment planning at MBPCC.  The digitizer is only used for Pinnacle3 when a block 
needs to be input to Pinnacle3.  It has already been proven that the digitizer would 
become broken or inaccurate after being used for a long time (Curran et al, 1991).  
Therefore, based on the thought of testing device functions in clinical use, the digitizer 
accuracy in block input is only tested semi-annually. 
With a piece of graph paper on the view box, the origin of the coordinate was 
defined first.  Centered by this point, a 10 X 10 square was digitized.  The coordinate of 
the four vertices should be (5,5), (-5,5), (-5, -5) and (5, -5).  Look up the coordinate 
reading in Pinnacle3 and find out the difference.  Also, the block picture was printed out 
and the side length of the square in the picture was measured.  It is expected to be 10cm 
each. 
4.2.6 Criteria of Acceptability 
Based on TG-40 and our own situation, the following criteria is recommended 
(Table 4.3). 
Table 4.3 Recommendation on the criteria of TPS QA 
Comparison Tolerance 
Point Dose at Hi gradient area 2% or 2mm 
Point Dose at Low gradient area 1% 
Dose profile 1mm 
DVH 1mm or 1 unit position off 
Isodose line 1mm 
DRR 1mm 
Printout 1mm 
Digitizer 1mm 
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4.2.7 Documentation of Pinnacle3 
Our Pinnacle3 already has all the recommended documents in Danlin’s paper.  In 
addition, a notebook was supplemented to record any possible limitations of the Pinnacle3 
system as found by dosimetriests.  Discussions between the physicists and dosimetrists 
are necessary. 
4.2.8 Test Frequency 
From July to August, QA tests were performed every week to verify the reliability 
of our QA test.  Recently, the frequency has been reduced to once every two weeks.  In 
the future, one machine QA plan monthly is recommended.  If the system keeps working 
well, it can be extended to quarterly. 
In addition, there are four conditions that will necessitate a repetition of the QA 
plan or setting up a new reference plan. 
• Software changes on TPS 
• New/altered data files 
• CT image software/hardware change 
• Machine output changes 
The new reference plan can get whole treatment parameters transferred from the 
old reference plan instead of an actual patient.  In some cases, the latest QA plan can also 
be considered a reference plan. 
4.2.9 Annual Pinnacle3 QA (or Recommissioning) 
Every accelerator is calibrated annually.  Parameters measured include cone ratio, 
wedge factor, tray factor, off axis factor and depth dose.  The result was compared with 
the Pinnacle3 input to ensure no changes in machine output. 
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Annually, it is recommended that the ongoing QA result be reviewed to determine 
what is already being done and what additional tests may be required.  Additionally, the 
entire machine file database should be rechecked by the sum program. 
4.2.10 Pinnacle3 Individual Test 
Besides making a QA plan on the newly scanned phantom image series from CT, 
a QA plan may also be made using reference plan phantom images stored in Pinnacle3.  
In this way, the QA plan has the same images as the reference plan and the final plan 
report should be exactly the same.  This test can be used to verify Pinnacle3 software 
when CT- Pinnacle3 integrated QA test result shows any error. 
4.2.11 Software Upgrade Test 
In September 2002, MBPCC Philips computers were upgraded from Pinnacle3 6.0 
to Pinnacle3 6.2 planning tool software.  The new features include the following. 
1. DICOM Derived: Pinnacle3 can capture a DRR image and send it to a Record & 
Verify system (IMPAC). 
2. Block output: We can add block numbers/names in the Beams spreadsheet and 
through SmartSim. 
The new software also fixes some problems found in Version 6.0s. 
1. If you import a dataset that contains negative CT numbers, Pinnacle3 now warns 
you and gives you the opportunity to clip the negative numbers. 
2. Previously, exported dose from the planar dose window could be mirrored and/or 
rotated.  The dose is now correctly oriented in the output files with respect to the 
planar dose window. 
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According to the Pinnacle3 6.2 released notes (2002) provided by Philips ADAC 
laboratory, there is no change of dose calculation algorithm in the new software.  
Therefore, the QA plan should still be the same as the reference plan. 
4.3 Result and Analyses 
4.3.1 Checksum 
All the check results are the same as reference, which shows the stability of 
Pinnacle3 database. 
4.3.2 Reference Case Comparison 
4.3.2.1 Point Dose 
The point dose comparison between the 21EX(BR) reference plan and QA plan is 
summarized in the table 4.4,4.5,4.6 and figure 4.4, 4.5, 4.6. 
From the tables and figures, it is clear that the change of entire point doses was 
within the tolerance.  Pinnacle3 calculation has not been altered during the test period. 
However, if one point dose is significantly different but the other point doses are 
correct, the point dose 1mm around the divergent point can be checked for those points at 
high dose gradient region.  For other points (low dose gradient region), the dose from 
each beam or source to surface distance (SSD) of each beam needs to be verified first.  If 
one of the beam doses is changed beyond the tolerance while other beam doses remain 
the same, we can sum check the single beam measured database file to see if there is any 
change in the input data of this beam. 
On the other hand, if the entire point doses are totally inconsistent, Pinnacle3 and 
CT have to be tested individually.  The Pinnacle3 individual QA is described in this 
chapter and CT individual QA would be in the next chapter. 
   
 
32
Table 4.4 Point dose comparison (1) between 21EX(BR) reference plan and QA plan 
Points/dose ISO Laser Point A Pt Inside Tumor A Pt Inside PTV 
Jan 28 5224.04 5100.59 5260.68 5242.65 
Jul 1 5227.32 5111.66 5265.97 5246.66 
Jul 14 5234.23 5115.41 5266.01 5244.04 
Jul 24 5225.70 5109.11 5258.71 5237.13 
Aug 2 5224.49 5109.62 5263.25 5239.83 
Aug 13  5216.55 5099.84 5250.68 5228.13 
Aug 21 5231.13 5093.91 5242.36 5217.7 
 
Table 4.5 Point dose comparison (2) between 21EX(BR) reference plan and QA plan 
Points/dose Pt1 at Hi gra Pt2 at Hi gra Pt3 at Hi gra Pt4 at Hi gra 
Jan 28 4534.02 4467.05 3504.44 4155.18 
Jul 1 4551.51 4484.17 3508.11 4167.57 
Jul 14 4538.86 4495.03 3497.42 4162.15 
Jul 24 4540.99 4491.25 3497.92 4163.30 
Aug 1 4544.85 4490.55 3500.91 4166.73 
Aug 13 4531.18 4481.16 3486.41 4152.72 
Aug 21 4526.28 4475.66 3479.41 4152.82 
 
Table 4.6 Point dose comparison (3) between 21EX(BR) reference plan and QA plan 
Points/dose Pt1 at low gra Pt2 at low gra Pt3 at low gra Pt4 at low gra 
Jan 28 1301.44 736.37 1898.20 2022.04 
Jul 1 1312.65 739.25 1925.89 2027.18 
Jul 14 1322.43 740.78 1923.11 2011.66 
Jul 24 1310.28 734.77 1918.91 2004.70 
Aug 1 1313.15 737.10 1909.66 2022.99 
Aug 13 1306.29 732.52 1917.00 2004.35 
Aug 21 1309.65 731.09 1923.24 2023.81 
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(Figure cont’d) 
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4.3.2.2 Monitor Unit 
Table 4.7 illustrated the monitor unit calculation tracking in the QA plan of 
21EX(Baton Rouge) machine. 
Table 4.7 Monitor Unit per fraction comparison in 21EX(BR) QA plans 
Date\Beam 265 Brain 180 Brain 95 Brain LSO Brain Vertex Brain RSO Brain
Jan 28 46 81 50 53 72 56 
Jul 1 46 81 50 53 72 56 
Jul 14 46 82 50 52 71 55 
Jul 24 46 82 50 52 71 55 
Aug 1 46 82 50 52 71 55 
Aug 13 46 82 50 52 71 55 
Aug 21 46 82 50 52 71 55 
 
 For LSO Brain and RSO Brain beams, the monitor unit has been changed by 1 
and it is close to our 2% criteria.  The reason for the change is because it was only 
determined out how to keep everything (contours and POI) in the same relative position 
after July 14.  The small shift in relative positions makes a slight difference in SSD 
(Source Surface Distance), which leads to the changes in monitor unit calculations.  
Because of that, the QA plan in Jul 14 is considered as the new reference plan. 
4.3.2.3 DVH Result 
All of the DVH plot print out and data table turn out to be in a good agreement 
with the reference plan. 
4.3.2.4 Monitor Display and Printout Accuracy 
The length (AP/PA) and width (Lateral) of the radiosurgery phantom were 
measured by a caliper and ruler.  Compared to the measurement on the printout, and the 
result is summarized in table 4.8.  The scale in Pinnacle3 printout is 5cm/actual length of 
the five segments. 
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Table 4.8 Dimension measurement on Monitor Display and printout compared to 
the caliper measurement 
Unit (cm) Lateral side AP/PA side 
Measurement by Caliper  16.50  20.01 
Measurement by Ruler 16.45 20.00 
Printout (scale 1) 7.2/2.2 x 5 =16.36cm 8.8/2.2 x 5 = 20.0cm 
Different from Caliper -0.85% 0.0% 
Printout (scale 2) 6.52/2.0 x 5 =16.30cm 8.0/2.0 x 5 = 20.0cm 
Different from Caliper -1.21% 0.0% 
Printout (scale 3) N/A 6.0/1.5 x 5 = 20.0cm 
Different from Caliper N/A 0.0% 
 
From the result, it is demonstrated that the input fits to the printout in different 
scales. 
4.3.2.5 Accuracy of DRR (Digital Reconstructed Radiographs) 
The paper picture of 6 DRR from 6 beams and one DRR picture on the film were 
compared to the reference plan printout.  On a viewbox, there is no visible change. 
4.3.3 Digitizer Test 
The result is demonstrated in table 4.9 and 4.10. 
Table 4.9 Points coordinate comparison in digitizer test 
All in mm Expected value ADAD reading Difference 
Point 1 (-5, 5) (-4.9657, 5.00634) (0.0343, 0.00643) 
Point 2 (-5, -5) (-5.0165, -4.9911) (-0.0165, 0.0089) 
Point 3 (5, -5) (4.98094, -5.0292) (0.01906, -0.0292) 
Point 4 (5, 5) (5.03936, 4.95808) (0.03936, -0.04192) 
 
Table 4.10 Length measurement comparison in digitizer test 
All in mm Expected value Ruler measurement Difference 
Side length 1 10 10.1 +0.1 
Side length 2 10 10.2 +0.2 
Side length 3 10 9.9 -0.1 
Side length 4 10 10.0 0.0 
 
From the tables above, it is safe to say that the digitizer is working properly with 
meeting the criteria of 1mm. 
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4.3.4 Pinnacle3 Individual Test 
The 2100C reference plan was transferred to a July 24 image series in July 25.  
Two months later, the same plan was transferred to the same image series.  The exact 
point dose, monitor unit per fraction, DVH, etc. were achieved.  The point doses are even 
the same to the hundredths place. 
Table 4.11 Dose comparison in Pinnacle3 individual test 
Points Reference plan After software upgrade Difference 
ISO 6000.28 6000.28 0.0 
Tumor Center 6019.53 6019.53 0.0 
Pt1 around tumor 5895.64 5895.64 0.0 
Pt2 around tumor 5542.66 5542.66 0.0 
Pt1 at hi dose 
gradient region 
5879.53 5879.53 0.0 
Pt2 at hi dose 
gradient region 
5790.64 5790.64 0.0 
Pt3 at hi dose 
gradient region 
5319.81 5319.81 0.0 
Pt4 at hi dose 
gradient region 
5364.60 5364.60 0.0 
 
4.3.5 Software Upgrade 
After the software upgrade, all of the reference plan doses were recalculated by 
the new software in version 6.2.  Again, the result were exactly the same as before. 
Next, the QA head phantom was scanned, and the CT- Pinnacle3 integration QA 
test was performed.  It was found that the coordinate of the point aligning with the B. B. 
markers (laser point) changed from (-0.41, 0.08, 0.00) to (-0.47, -28.08, 0.00).  It is a 
28.16cm difference in anterior and posterior direction.  The possible reasons have not yet 
been determined. 
In order to repeat our QA test, the coordinate of isocenter and other POIs were 
adjusted to keep them at the same relative position in the images as before. The results of 
recalculations (2000CR, Hammond) are shown in table 4.12. 
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Table 4.12 Point dose comparison after Pinnacle3 software upgrade 
Points Reference plan After software upgrade Difference 
ISO 6000.28 5998.76 -0.025% 
Tumor Center 6019.53 6022.61 +0.051% 
Pt1 around tumor 5895.64 5871.37 -0.412% 
Pt2 around tumor 5542.66 5531.24 -0.206% 
Pt1 at hi dose 
gradient region 
5879.53 5874.49 -0.086% 
Pt2 at hi dose 
gradient region 
5790.64 5805.07 +0.249% 
Pt3 at hi dose 
gradient region 
5319.81 5240.13 -1.50% 
Pt4 at hi dose 
gradient region 
5364.60 5352.16 -0.232% 
 
It is noticed that although the coordinate of the laser point changed as large as 
28cm in anterior and posterior direction, it doesn’t affect the dose calculation of the 
Pinnacle3 calculation at all.  Also because the coordinate is not an absolute value, it 
doesn’t change the patient treatment either, as long as the isocenter has the same relative 
position compared to its position in CT-simulator couch. 
4.4 Discussion 
The following are some possible further tests and discussion on CT- Pinnacle3 
integrated QA. 
4.4.1 Checking of Data Transfer from CT to Pinnacle3 by Checksum Program 
Both CT-simulator and treatment planning computers at MBPCC have a Unix 
operating system.  Although the computers are made from different companies, the same 
signatures come out after a test file is executed by the “sum” command in both 
computers.  Therefore it is possible to sum check the image files before and after the 
image transfer by DICOM to see if the image files give the same signature.  But 
unfortunately, a series of CT images would be combined into one file named 
PATIENT_image in Pinnacle3.  They are not same type of files any more. 
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4.4.2 Pinnacle3 IMRT Planning Repeat Test 
IMRT planning calculation is usually complicated and takes a long time to 
achieve optimization.  It would be valuable to see if the computer can give us the same 
result given exactly same initial condition, such as the objectives and constraints.  In this 
way, the Pinnacle3 software constancy is also verified. 
4.4.3 Accuracy of DRR (Digital Reconstructed Radiographs) 
Russell et al (1996) recommend comparing plane film radiographs taken on a 
conventional simulator and DRR generated from scan of a diagnostic phantom.  
Comparisons need to include simple anterior, posterior and complex geometries 
combining gantry and table rotation. 
4.4.4 Pinnacle3 and CT Tape Saving Test 
At MBPCC, all of the patients’ images data are saved in CT tapes while all of the 
patients’ plans are saved in Pinnacle3 tape.  It is necessary to ensure the accuracy of these 
savings because physician may want to have a look at a patient’s plan again.  An image 
series was restored from the CT and Pinnacle3 tapes, and QA plans were repeated.  The 
result appeared exactly the same as the reference plan, which showed the excellent 
accuracy of the treatment plan and CT images archive. 
4.4.5 Impractical Implementation of Treatment Plan 
Sometimes, a patient plan may be unable to be implemented in accelerators 
although it may look perfect at Pinnacle3.  For example, the gantry would hit couch when 
gantry angle and couch angle are at 270o and 90o respectively.  This error can’t be found 
until patient starts his/her treatment.  There must be still other similar minor problems in 
Pinnacle3.  It would be good to point them out and educate every Pinnacle3 user. 
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4.4.6 Other Tests 
Although we test the CT- Pinnacle3 integrated process, sometimes the images are 
imported from MRI or PET and then combined with CT images to get better results.  
Therefore, it is necessary to set up QA test on the image fusion accuracy.  This is a hot 
topic right now. 
4.5 Conclusion 
A Pinnacle3 QA procedure was built up by simulating the real patient treatment 
process.  It is fast and effective, although it is not perfect.  However, it can correctly show 
any systematic error happening in the treatment planning process before the error leads to 
a worse result.  Overall, it is good enough for ongoing TPS QA.  It only takes less than 
one hour to complete the whole QA test. 
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CHAPTER 5 CT-SIMULATOR QA 
5.1 Introduction 
Besides the CT- Pinnacle3 integrated QA, the CT-Simulator QA is also critical, especially 
when there is any error in the CT- Pinnacle3 integrated QA result and Pinnacle3 software 
individual QA shows there is no problem in Pinnacle3 itself.  In this study, a CT-
simulator ongoing QA procedure is also set up to obtain earlier detection and prevent 
small errors before they get worse. 
5.1.1 CT-Simulator History 
Conventional simulators have been used for more than 30 years and provided 
quite limited anatomical information.  Conversely, CT images provide much more 
information.  In 1983, Goitein and Abrans described a multi-dimensional treatment 
planning based on CT images.  They introduced beams eye view (BEV) and usage of 
films created from a divergent projection through the CT study data.  Later from 1987 to 
1990, Sherous et. al reported a system that is called software analog to conventional 
simulation.  The idea was to use volumetric sets of CT scans to represent virtual patients.  
The software functions create a virtual simulator.  In 1990, Nishidal et al and Nagata et al 
proposed CT simulator systems with laser beam projecting device.  Following that, 
commercial CT simulator systems were released in 1993. 
5.1.2 CT-Simulator Principle 
The CT-Simulator is different from the conventional CTs both in purpose and 
functionality.  By performing a simulation on a computer generated or virtual image of 
the patient, CT-Simulator successfully eliminates the need to perform conventional 
treatment simulation.  The function of the CT-simulator consists of a conventional CT, a 
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dedicated computer workstation, and some type of laser patient marking system that is 
used to define either a portal field shape or tumor volume isocenter on the patient’s skin 
surface (McGee et al. 2000). 
CT-Simulation is a unique process because it combines the isocenter localization 
aspects of conventional simulation with the acquisition of volumetric data through the use 
of virtual simulation software.  Integration of CT data acquisition into the treatment 
planning/simulation process allows more precise volume definition so that conformal 
beam arrangements with tighter margins may be used for daily treatment delivery. 
5.1.3 MBPCC Situation 
CT-simulation and 3-D radiation treatment planning systems were replacing the 
conventional simulator and 2-D dose planning systems by the end of last century.  About 
two years ago, MBPCC implemented a GE high speed CT-Simulator, which utilizes CT 
spiral scanning techniques, and interfaced it to 3-D treatment planning system (Pinnacle3) 
through DICOM (Digital Image Communication in Medicine).  This new technology is 
providing advanced tools for planning, implementing and evaluating much more complex 
treatment techniques in an effort to improve tumor control and reduce the morbidity of 
treatment for cancer patients.  However, it also brings medical physicists new challenges 
to ensure proper performance.  Currently, only the CT technician performs the daily QA, 
and no any monthly or annual QA has been done. 
5.2 Literature Review 
Russell et al, (1996) proposed that the main aims of CT-Simulator QA included: 
• CT image quality 
• Isocenter localization / laser alignment  
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• Reconciliation of coordinate systems 
• Immobilization device registration 
• Accuracy of digital reconstructed radiographs 
• Computer network / data transfer issues 
For the more complicated CT-Simulator, stricter QA procedure should be 
imposed to assure the correct simulation process.  These procedures are the responsibility 
of both therapists and physicists.  CT technicians are in charge of the daily QA required 
by State Department of Environmental Quality, while physicists are responsible for 
setting up the daily QA procedure for therapists and for performing monthly and annual 
QA. 
In the recent AAPM 45th annual meeting, Lawrence (2002) suggested that 
Preventive Maintenance and Quality Control should include: 
• Proper performance of x-ray units 
• Optimum Image Quality 
• Minimum Dose to Patients 
• Problems Found before seriously affecting 
Image quality, and patient & Personnel Safety 
• Avoid repeats 
Save Time & Money 
More specifically, his experience at Memorial Kettering Sloan Cancer Center 
(MKSCC) can be summarized as table 5.1. 
Realizing the importance of the CT-Simulator, AAPM is organizing a task group 
to work on the summary of CT-simulator QA.  The report will be published in 2003. 
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Table 5.1. Summary of CT-Simulator QA at MKSCC 
Frequency TEST 
Noise Weekly test 
CT number in Water 
CT Number Uniformity 
Low Contrast Resolution 
High Contrast Spatial Resolution 
 
Monthly test 
Hard Copy Output Devices 
All Weekly and Quarterly Tests 
Laser Alignment 
Slice Thickness 
Low Contrast Resolution 
High Contrast Resolution 
Index Accuracy and Couch Positioning 
Contrast Scale 
Linearity of CT# with attenuation coefficient 
 
 
 
 
Semi-Annual Tests 
Distance Accuracy 
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5.3 Methodology 
The CT individual test is to check the CT number constancy in CT images of the 
radiosurgery phantom. 
5.3.1 Physical Density to CT Number Conversion Consistence 
In ADAC, the density information inherent in the patient CT images is used to 
account for tissue inhomogeneity in Pinnacle3 photon and electron dose calculations 
(Pinnacle3 Physics Manual, 2001).  During the planning procedure, Pinnacle reads in the 
CT numbers and then determines the density for each voxel of the patient using the 
selected CT to Density table.  The density is used to look up mass attenuation coefficients 
and is used for density scaling during superposition.  Pinnacle3 uses mass attenuation 
coefficient tables stored for several material types in determining the TERMA 
distribution in heterogeneous media.  Each material-specific table is stored with its 
physical density.  The mass attenuation coefficient for each density in the CT volume is 
then determined through linear interpolation between the materials closest in physical 
density.  This allows Pinnacle3 to account for the different material types that may be 
present in the treatment volume. 
The physical density is also used to scale the dose deposition kernel during the 
superposition to account for the effects of heterogeneities on scattered radiation.  This is 
accomplished by tracing a ray line between TERMA interaction site and the dose 
computation point, and accumulating the radiological distance along the ray during the 
superposition. 
It is easy to see from above that the density information entered in this table is 
critical to correct dose calculations.  Failure to specify the CT to density table for a CT 
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scanner used to obtain treatment-planning images may result in erroneous dose 
calculations. 
In addition, it is already known that physical density to CT number conversion 
keeps changing.  Russell et al. (1996) recommend checking it every month.  Since the 
head phantom is scanned in our test, checking the consistency of CT number in the head 
phantom is a good substitution and requires no additional scans.  CT numbers and their 
standard deviation in 14 specific regions have been recorded.  Whenever the test is 
necessary, the CT# in those 14 specific regions are reread to see if they have changed. 
5.3.2 Ongoing CT QA 
Besides the CT number constancy check, an ongoing CT QA procedure is also 
established in order to assure consistent image quality.  If the tests are repeated 
frequently, changes in image quality values can be noticed before the problem gets 
worse.  The current QA frequency mainly is based on the recommendation of Lawrence 
(2001) and the need for the CT-simulator. 
5.3.3 QA Equipment 
The main equipment used in the ongoing CT-Simulator QA is a quality assurance 
phantom provided with the CT-Simulator.  This phantom contains three sections, each 
corresponding to a single scan plane (Figure 5.1).  The phantom is placed on a holder, 
connected to the couch (Figure 5.2) and scanned with parameters set up in Table 5.2. 
Table 5.2 CT scan technique of ADAC QA Phantom 
Scan method KV mA Thickness Gantry Ang Total Slices 
Axial full 3.0 sec 120 100 10mm 0.0 3 
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Figure 5.1 Three sections of CT QA phantom 
 
 
 
Figure 5.2 CT QA phantom connecting to CT couch 
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5.3.4 Daily QA  
Daily QA includes contrast scale, and noise test. 
5.3.4.1 Noise 
Noise equals the standard deviation of an array of pixels contained in 674mm2 
region of interest (ROI) for head and 2696 mm2 ROI for body.  The noise squared in a 
CT image is inversely proportional to the x-ray dose used to make the image.  A region of 
interest in water was enclosed, and the software calculates and displays the standard 
deviation or noise of the pixels inside.  The maximum anticipated for image noise is 30%. 
5.3.4.2 Contrast Scale 
For the test propose, CT values of water and acrylic in the QA phantom were 
tracked to assure the contrast scale constancy.  The difference in CT numbers between 
the Plexiglas resolution block and water should equal 118, with a suggested allowable 
variation of 10%. 
5.3.5 Weekly QA 
On a weekly basis, the laser will be checked by the CT technician. 
In radiation oncology, fast and reproducible positioning of patients is of major 
importance to ensure an accurate dosage of radiation in tumor volume.  Especially after 
the implementation of IMRT, the requirement for high accuracy in determining the 
location has been raised even higher.  A laser system is one of the most important devices 
to get this type of accuracy.  The laser system with the CT-simulator at MBPCC is LAP 
PatPos CT1-3 from LASER APPLICATIONS L.C. 
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The laser checking does not just simply align the laser with a mechanical device.  
A WILKE phantom is used, which is shown as figure 5.3.  The WILKE phantom is 
aligned with the internal laser and scanned by the technique listed in table 5.3. 
Table 5.3 CT scan techniques in LASER check 
Scan method KV mA Thickness Gantry Ang Total Slices 
Axial full 1.0 sec 80 80 3mm 0.0 2 
 
 
Figure 5.3 WILKE Phantom 
 
The phantom has 8 grooves on its side.  It is first confirmed that none of the 
grooves along the edge of the WILKE phantom are visible, and then the couch is brought 
out 10mm, and the scan is repeated.  Four grooves should be visible now.  Bring up grids 
on the image and the up, down, left and right grooves should be aligned with the grids 
very well.  If not, add a piece of paper under the phantom and repeat the procedure until 
the grooves are aligned with the grids.  The WILKE phantom is now aligned with the 
isocenter of the scanner.  The next step is to move the couch out 600mm, which should 
be the distance between the isocenter and the outside laser.  Now we can align the outside 
laser to the WILKE phantom. 
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5.3.6 Monthly QA 
Monthly QA includes: 
5.3.6.1 High Contrast Spatial Resolution  
Two different alternatives are available to test high contrast spatial resolution.  
The first is to test six sets of bar patterns in a Plexiglas block, as shown in figure 5.1.  
Each pattern consists of sets of equal-sized bars and spaces, in the following sizes: 
1.6mm, 1.3mm, 1.0mm, 0.8mm, 0.6mm, and 0.5mm.  Examine the bar patterns to find 
the smallest bar pattern we can see clearly. 
The second method is associated with measuring the standard deviation of the 
pixel values in a single or multiple bar pattern.  ROI standard deviation provides a good 
indicator of system resolution and a sensitive method to detect changes in system 
resolution.  For example, the standard deviation for an ROI in the 1.6 mm bar pattern 
should equal 36 HU, with a suggested allowable variation of 20%. 
5.3.6.2 CT Number Uniformity 
CT numbers of water in three different water regions can be tested in QA 
phantom section 3.  The difference among those CT numbers should not be larger than 
the standard deviation. 
5.3.6.3 Low Contrast Detectability 
The second section of QA phantom includes a series of holes with 10.0mm, 
7.5mm, 5.0mm, 3.0mm, and 1.5mm diameters (Figure 5.1).  The smallest hole size 
visible at a given contrast level with given dose is defined as the low contrast 
detectability.  
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5.3.7 Annual QA 
Besides reviewing daily QA and monthly QA result, annual QA also includes. 
5.3.7.1 Slice Thickness 
Slice thickness can also be measured by the QA phantom supplied with the CT.  
However, a better method is to use GAMMEX Phantom with a helix insert.  The insert 
has a spiral wire inside.  After the CT scan, every slice image would have a white point 
responding to the wire.  This point also rotates gradually as we go through slice by slice.  
When the point goes back to the original position, count how many slices it goes through.  
Use the length of the insert divided by the number of slices to determine the slice 
thickness. 
5.3.7.2 Dose and Performance for CT-Simulator Tube 
International Electrotechnical Commission (IEC) standard provides CTDI100  (CT 
dose index) for typical techniques at various positions on the phantom image (table 5.4).  
Figure 5.4 shows the position of those measurement points.  The typical technique 
parameters are listing in Table 5.4. 
Table 5.4 Typical technique parameters 
 Head Body 
Field of View 25 cm 50 cm 
kVp 120 kVp 120 kVp 
MA 150 mA 130 mA 
Scan time 2.0 sec 1.5 sec 
Slice thickness 10mm 10 mm 
Focus Large Large 
Table 5.5 CTDI100 (IEC standard) for Typical Technique at various positions on the 
phantom image (mGy) 
Position Head Body 
A 45 8.4 
B 46 17 
C 45 15 
D 45 13 
E 47 16 
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Figure 5.4 The measurement position of CTDI100 
A 10X5-3 CT ion chamber (RADCAL Corporation S/N 8024) was used with a 
cylinder head phantom (15cm long and 16cm in diameter) and a cylinder body phantom 
(15cm long and 32cm in diameter) made of acrylic, which as illustrated in figure 5.5 and 
5.6.  One is to simulate the head and the other is for body.  The CT ion chamber was 
connected to the RADCAL Model 1550 converter.  The exposure can directly read from 
the Model 1550 radiation monitor. 
 
Figure 5.5 Body phantom for CTDI100 measurement 
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Figure 5.6 Head Phantom for CTDI100 measurement 
 
Figure 5.7 CTDI100 measurement setup 
 
The formula to calculate CTDI100 is: 
RcGySTmmXCTDI /76.0/100100 ××=     (5.1) 
Where X is the exposure, 
     ST  is the slice thickness, 
 0.76 RcGy /  is the f factor for acrylic, 
Another test is to test CTDI100 ratio over a range of techniques.  Keep all the 
settings at typical technique value (shown on table 5.4), and change one of the settings.  
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Then normalize the readings to a value of 1 with CTDI100 typical technique at position A.  
The ratios are compared to IEC standard value. 
5.3.8 Physical Density to CT Number Calibration 
Although our CT-ADAC integrated QA test checks the CT number consistency of 
the CT-simulator scanning, it is still necessary to bring in a special CT number 
measurement phantom annually to check the CT number to the physical density 
conversion table.  The phantom used is CIRS Model 62 electron density calibration 
phantom, which is demonstrated in Figure 5.8.  It has many rods inside and the rods 
contain different physical density material.  After scanning the phantom in the CT-
Simulator, the average CT number in these rods was recorded and a conversion table 
between the physical density and Pinnacle3 CT number can be obtained.  The Pinnacle3 
uses a modified CT number, which is equal to the usual CT number plus 1000.  The scan 
technique is the way a CT technician scans the abdomen or thorax part of the body, and it 
is shown in the following table 5.6. 
Table 5.6 CT scan technique for electron density calibration phantom 
Scan method KV mA Thickness Gantry Ang Total Slices Focus 
Helix full 1.0 sec 120 150 3mm 0.0 21 Large 
 
 
Figure 5.8 CIRS Model 62 electron density calibration phantom 
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5.4 Result 
5.4.1 CT Number Consistence 
The results are summarized in table 5.7, figure 5.9 and 5.10. 
From the data above, it is easy to see that all of the CT number changes from July 
to September are within the standard deviation. 
5.4.2 QA Measurement Summary 
Table 5.8 is the summary of the CT QA measurement. 
5.4.3 Noise Variation 
From May to October, the noise variation is shown in table 5.9 and figure 5.11.  It 
is clear that the image noise is less than the tolerance, which is 30%. 
Table 5.9 Measurement of CT image noise from May to October 
 May June July August September October 
Noise 25% 27% 28% 29% 27% 29% 
 
CT Image Noise Deviation
Month
4 5 6 7 8 9 10 11
N
oi
se
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
 
Figure 5.11 Noise Variation from May to September 
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Table 5.7 CT number consistence test from July to September 
 Measurement Area July 15 Aug 13 Sep 17 
Pts Area (mm2)  Center CT # SD CT # SD CT # SD 
1 50 (0, 63.4, 72.0) 609.40 30.43 609.55 29.09 603.67 34.88 
2 50 N/A 106.07 3.75 106.96 3.67 108.15 3.91 
3 50 N/A 635.01 8.06 638.20 10.23 641.60 11.21 
4 50 (20.8,59.6, 72) 652.44 7.43 644.29 8.2 653.14 7.47 
5 5 N/A 108.21 4.09 108.31 1.83 110.08 4.23 
6 N/A N/A -2.81 3.35 -1.64 3.27 -1.65 3.07 
7 100 (20.2,68,60) 622.23 6.29 623.90 8.84 620.52 8.44 
8 50 N/A 541.57 21.46 543.12 29.47 550.10 26.34 
9 100 (3.8,65.1,24.0) 625.99 3.95 633.68 12.82 628.52 7.09 
10 800 (4,35,12) 84.85 3.72 80.64 4.98 81.98 4.81 
11 130 (16,35,0) 105.53 4.14 106.74 3.76 107.42 3.59 
12 100 (0,13,0) 105.68 3.78 106.56 3.99 107.37 4.3 
13 150 (17.5,33,36) 47.51 3.82 54.96 3.80 53.60 3.93 
14 100 N/A 112.79 3.54 110.50 3.73 113.19 3.04 
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Figure 5.9 CT# consistence comparison (1) from July to September 
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Figure 5.10 CT# consistence comparison (2) from July to September 
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Table 5.8 Results summary of Ongoing CT-Simulator QA 
TEST 
MEASUREMENT 
TOLERANCE MEASURED 
VALUE 
PASS OR FAIL 
 
CT number in water 
 
0 +/- 5 
10mm slice = -0.7 
5mm slice =  -0.3 
3mm slice =  -0.2 
 
PASS 
Pixel noise 
(Standard 
Deviation) 
 
Deviation less than 30%
 
See figure 5.11 
 
PASS 
High Contrast 
Spatial Resolution 
SD for ROI of 1.6mm 
bar pattern is 36. 
Variation less than 20% 
 
See figure 5.12 
 
PASS 
Slice Thickness   PASS 
3mm slice 3mm +/- 0.5mm 3.5mm PASS 
5mm slice 5mm +/- 0.5mm 5mm PASS 
10mm slice 10mm +/- 0.5mm 10mm PASS 
CT number in air -1000 +/- 10 -997.72, SD = 2.99 PASS 
Water -0.03 PASS 
Membrane 9.03 PASS 
 
Top 
Difference 9.06 PASS 
Water 0.31 PASS 
Membrane 8.95 PASS 
 
Bottom 
Difference 9.26 PASS 
 
 
 
Low Contrast 
Hole 5 PASS 
CT # of water -0.01 PASS 
CT # of Plexiglas 120.48 PASS 
 
Contrast Scale 
Difference (118+/-10%) 120.47 PASS 
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5.4.4 High Contrast Spatial Resolution 
Table 5.10 is the measurement of standard deviation for an ROI in the 1.6mm bar 
pattern.  It indicates the change of high contrast spatial resolution.  The expected value is 
36 and the criterion is 20%, which means the tolerance range is [28.8, 43.2].  The results 
met our expectations. 
Table 5.10 Measurement of standard deviation from May to October 
 May June July August September October 
SD 34.46 36.14 35.55 35.76 34.85 35.43 
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Figure 5.12 High Contrast Spatial Resolution Variation from May to October 
 
5.4.5 Dose and Performance for CT-Simulator Tube 
5.4.5.1 CTDI100 for Typical Technique at Various Positions on the Phantom 
The readings from the Model 1550 radiation monitor is shown in table 5.11.  The 
unit is mR. 
Table 5.11 Reading of CTDI100 measurement 
Position Head Body 
A 502 77.3 
B 561 180.5 
C 518 152.6 
D 471 55.1 
E 512 106.3 
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Use equation 5.1, and the table 5.12 is the comparison between our CTDI100 
calculation result and IEC standard CTDI100 value. 
Table 5.12 CT Dose Index (CTDI100) measurement compared to IEC standard 
Unit: mGy Head Body 
Position Measurement IEC Measurement IEC 
A 38.1 45  5.87 8.4 
B 42.6 46 13.7 17 
C 39.4 45 11.6 15 
D 35.8 45 4.19 13 
E 39.0 47 8.08 16 
 
It is obvious that all of the CTDI100 measurements are less than the IEC standard, 
but also very close to them, which is what was expected. 
5.4.5.2 CTDI100 over a Range of Techniques 
The test result of the dose CTDI100 ratio over a range of technique is illustrated in 
table 5.13 and 5.14.  The data in these tables shows us our CT-simulator works very well.  
Most of the ratios are equal to or very close to IEC standard values.  The difference is 
negligible. 
 5.4.6 Physical Density to CT Number Conversion Table 
The new Physical density to CT number conversion table is shown as table 5.15 
and figure 5.13. 
5.5 Discussion 
5.5.1 Mechanical Test 
Other CT-Simulator tests like gantry angle, table in/out and table height are also 
performed in the CT QA process.  Because these checks are very similar to the usual 
accelerator mechanical tests, they are not described here. 
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Table 5.13 CTDI100 ratio value over a range of techniques in Head phantom 
compared to IEC standard 
Head 
Technique A Reading (mR) Ratio IEC standard Difference 
Typical Technique A 502 1.0 1.0 0.0 
10 mA A 30.9 0.06 0.07 0.01 
300 mA A 948 1.89 N/A N/A 
0.8 sec A 236 0.47 0.40 +0.07 
3.0 sec A 699 1.39 1.50 -0.11 
7.0 sec A 322 0.64 0.69 -0.05 
5.0 mm A 231 0.46 0.49 -0.03 
3.0 mm A 137 0.27 0.30 -0.03 
2.0 mm A 91.2 0.18 0.21 -0.03 
1.0 mm A 51.6 0.10 0.12 -0.02 
80 kV A 154.6 0.31 0.32 -0.01 
140 kV A 672 1.34 1.43 -0.09 
 
Table 5.14 CTDI100 ratio value over a range of techniques in Body phantom 
compared to IEC standard 
Body 
Technique A Reading (mR) Ratio IEC standard Difference 
Typical Technique A 77.3 1.0 1.0 0.0 
10 mA A 5.87 0.08 0.08 0.0 
300 mA A 180.6 2.34 N/A N/A 
0.8 sec A 51.8 0.67 0.54 +0.13 
3.0 sec A N/A N/A 2.00 N/A 
7.0 sec A 53.4 0.69 0.70 -0.01 
5.0 mm A 38.4 0.50 0.50 0.0 
3.0 mm A 9.89 0.13 0.30 -0.17 
2.0 mm A 8.30 0.11 0.21 -0.10 
1.0 mm A 8.40 0.11 0.12 -0.01 
80 kV A 20.9 0.27 0.27 0.0 
140 kV A 115.7 1.50 1.50 0.0 
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Table 5.15 Physical Density to CT number conversion table in 2002 
Inserts 
Physical 
Density 
Inside Ring CT
Number 
Outside Ring 
CT Number 
Average CT 
Number 
ADAC CT 
number 
Lung (inhale) 0.195 -801.0 -804.8 -802.9 197.1 
Lung (exhale) 0.465 -484.0 -496.3 -490.2 509.8 
Adipose 0.967 -72.2 -73.7 -72.9 927.1 
Breast (50/50) 0.991 -35.4 -37.7 -36.5 963.5 
H2O in syringe 1.000 -5.7 -5.7 -5.7 994.3 
Muscle 1.062 43.6 44.8 44.2 1044.2 
Liver 1.071 54.3 51.8 53.0 1053.0 
Trabecular Bone 1.161 239.2 232.1 235.6 1235.6 
Dense Bone 1.609 925.1 924.8 925.0 1925.0 
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Figure 5.13 Physical density to CT number conversion table comparison  
in 2001 and 2002 
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5.5.2 Laser Checking Frequency 
The other reason why the CT laser is checked very frequently (weekly) is that our 
CT laser source is hanging on a wall adjacent to the door.  Whenever the door is closed, it 
makes the wall shake.  It is likely that the shaking would cause the CT laser source to 
move slightly each time.  And the fact is that CT-technician does find laser off slightly 
every week.  The laser checking procedure shows that the CT laser checking is based on 
the assumption that the grid system on the monitor is always correct.  Some other method 
is necessary to verify the accuracy the grid system. 
5.6 Conclusion 
CT-simulator individual QA procedures were set up.  It properly monitors the CT-
simulator working conditions.  Major parameters, such as CT number to physical density 
conversion, laser position and CTDI are measured or tested.  The ongoing CT-Simulator 
QA tests can get an early intervention and prevent a major breakdown. 
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CHAPTER 6 VARIAN VARISEED 6.7 QA  
6.1 Introduction 
Varian VariSeed 6.7 is the prostate implant brachytherapy planning system used 
at Mary Bird Perkins Cancer Center.  It consists of VariSeed software, a laptop computer, 
digitizer, and output devices.  The VariSeed software includes program files, data files, 
and a database system.  Although VariSeed 6.7 doesn’t support real time operation 
procedures, which has higher requirements of QA, it is still necessary to make sure of the 
accuracy of the treatment planning.  On average, there are about 8 cases per month at 
MBPCC including Baton Rouge and Covington. 
6.2 Literature Review 
Relatively few documents can be found with respect to QA of brachytherapy 
treatment planning systems.  And the AAPM Task Group report 56 (Code of Practice for 
Brachytherapy Physics) only mentions that QA of brachytherapy treatment planning 
computers should be established and performed, but without any comments. 
6.3 Methodology 
At MBPCC, the input images of the VariSeed planning system are directly 
downloaded from an ultrasound machine.  Since the ultrasound machine belongs to Our 
Lady of the Lake Hospital (OLOL), it is OLOL, who should be responsible for the QA of 
this component.  To make sure the other part of planning system is working properly, the 
best way to check the VariSeed 6.7 is still to repeat the actual patient treatment planning 
process.  By using this method, the entire process including template registration, the 
automatic seed placement function, the seed position selection and contour plotting by 
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the mouse method and all the other TPS characters used for patient treatment, can be 
verified. 
6.3.1 Reference Treatment Plan 
An image series (13 images) was imported to the planning system from a actual 
patient ultrasound image video.  Then, the ultrasound template registration points were 
marked and prostate structure contours were outlined.  Automatically, seeds were placed 
and some slight changes were made in source positions.  Only 100% and 150% isodose 
lines were used to show dose distribution as is standard practice of dosimetrists.  Semi-
annually, the treatment plan is repeated on the same image series and compared to the 
reference plan. 
Uncertainty in the estimation in brachytherapy calculations are much more 
difficult than external beams because of the short treatment distances and the following 
high dose gradients.   Van Dyke et al. (1993) gave a 5% criterion as the brachytherapy 
calculation with a single point source at 0.5 to 5.0 cm away from the source.  Since this 
QA test checks the software reproducibility instead of the calculation accuracy against 
measurement, 1% is chosen as comparison criteria. 
If there is any difference beyond the tolerance in the treatment plan comparison, 
individual function verification of the planning system needs to be performed.  There are 
three internal user test procedures inside the software itself. 
• Dose Calculation Verification Test Using a Dose Point 
• Dose Calculation Verification Test Using Isodose Contours 
• DVH and CVA (Contiguous Volume Analysis) Results Test 
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6.3.2 Dose Calculation Verification Test Using a Dose Point 
In the software, a source was placed at a tandem point and the dose at 0.5cm, 
1cm, … and 7.0cm away from the source were calculated.  In the manual of each type of 
sources, there are point dose lists at different distances calculated manually.  Table 6.1 is  
an example.  The point dose calculation by the software was compared to these manual 
calculation tables, and the result should be the same or nearly the same. 
The manual calculation tables are derived from the following formula. 
×= doseratedose
100
apptime       (6.1) 
The dose rate is calculated in three ways. 
1. With anisotropy constant: 
an
k rg
r
S
dtrdD ΦΛ= )(/)( 2       (6.2) 
2. With anisotropy factor values: 
)()(/)( 2 rrgr
S
dtrdD an
k ΦΛ=       (6.3) 
3. Without any anisotropy correction      
)(/)( 2 rgr
S
dtrdD k
Λ=  
Where  
 =dtrdD /)( dose rate (cGy/hr) 
  =r  radius 
 =kS air kerma strength 
 =Λ  dose rate constant 
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Table 6.1 Hand Calculation of Total Dose (Gy) for a 100 U 1–125 (STM1251) NIST 
1999 Source 
Distance in (cm) Anisotropy constant Anisotropy 
Factors 
No Anisotropy 
Correction 
0.50 7822.33 7830.64 8312.78 
1.00 1893.11 1895.12 2011.81 
1.50 788.38 787.12 837.81 
2.00 405.13 403.40 430.53 
2.50 233.84 234.09 248.50 
3.00 145.35 146.28 154.46 
3.50 94.58 94.88 100.51 
4.00 63.89 63.89 67.90 
4.50 44.41 44.34 47.19 
5.00 31.43 31.33 33.40 
5.50 22.81 22.77 24.24 
6.00 16.51 16.51 17.55 
6.50 12.32 12.34 13.09 
7.00 9.12 9.15 9.69 
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=)(rg radial dose function 
 =Φan anisotropy constant 
 =Φ )(ran anisotropy factor 
For permanent implants, the application time is calculated by: 
 (application time) = 1.44*24 hours/day * half-life 
All distances are in centimeters.  The half-life values are measured in days. 
6.3.3 Dose Calculation Verification Test Using Isodose Contours 
This test utilizes isodose contours to verify dose calculation.  At the same time, it 
also tests the proper isodose contour plot. 
A source was put in the 1st image of an 11 image series, and these images are 
0.5cm away from each other.  Manually, doses at 0.5, 1.00 … 4.5cm away from a point 
dose have been calculated (See example in table 6.2).  The calculation formula are 
equation 6.1 and 6.2. 
Table 6.2 Nine calculated isodose levels for Pd-103 (1031L) [NIST 1999] source 
Distance 
(cm) 
0.5 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 
Anisotropy 
Constant 
1772.07 364.92 126.02 53.74 25.87 13.26 7.33 4.11 2.41 
 
These doses were added as the isodose lines dose level to the software.  If the 
planning system calculation is correct, all nine isodose contours should be visible on 
image #1.  Each successive image should show one less isodose contour so that image #9 
has only one contour left from the lowest isodose level.  Also, the distance from the seed 
to each contour should be within +/-2 mm of the expected value (0.5cm, 1.0cm … 
4.5cm). 
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6.3.4 DVH and CVA Results Test 
This test is used to verify the accuracy of VariSeed DVH (Dose Volume 
Histogram) and CVA (Contiguous Volume Analysis) calculations and plotting. 
A point dose was placed in the center of a series of images.  The dose volume 
with 10Gy (Pd-103) and 100Gy (I-125) had been manually calculated by equation 6.4 
and 6.5. 
V = 4/3*πr3         (6.4) 
V = 1/3 δ*]*[ 11
2
0
++
−
=
++∑ iiiN
i
pApApA              (6.5) 
Equation 6.5 is the way VariSeed 6.7 calculates the dose volume.  The expression 
pA  represents the area of the structure on an individual slice or scan; i  indicates the scan 
or slice position (first, second, etc.); t  is the slice thickness; N is the number of slices 
(scans).  Table 6.3 is an example of dose volume calculation.  The VariSeed application 
uses a discrete representation of the dose, which causes the value of ipA  to deviate 
slightly from that of a perfect circle.  Thus, the values displayed in this column are 
different slightly from the values calculated by 4/3*πr3.  Our test results are expected to 
be close to the dose volume calculated by equation 6.5. 
Table 6.3 DVH and CVA results test data for the I-125 (MED3631-A/S) [NIST 99] 
source 
Activity U for: Dose Volume in cc for a Sphere 
of Radius r Using: 
 
Radius 
in cm Anisotropy 
Constant 
Anisotropy 
Factor 
4/3*πr3 Equation 6.5 
1.0 5.204 5.293 4.19 3.52 
1.5 12.605 13.100 14.14 13.04 
2.0 24.549 26.085 33.51 31.96 
2.5 42.686 43.336 65.45 63.43 
3.0 69.288 67.343 113.10 110.59 
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6.4 Result 
6.4.1 Reference Treatment Plan Comparison 
6.4.1.1 Dose Information 
Dose information comparison is the most quantitative way for the treatment plan 
comparison.  In the plan printout, it gives us the dose volume table and the volume dose 
table.  Table 6.4 and 6.5 are the comparisons between the reference plan and the QA plan. 
Table 6.4 Prostate dose volume comparisons 
 Reference plan QA Plan_1 
(cc) Abs Volume Per Volume Abs Volume Per Volume 
Total Volume 18.53 N/A 18.38 N/A 
V200 2.91 15.71% 2.82 15.33% 
V150 8.88 47.92% 8.82 47.97% 
V100 17.52 94.57% 17.37 94.51% 
V90 18.04 97.38% 17.93 97.58% 
V80 18.30 98.73% 18.15 98.74% 
V50 18.53 100% 18.38 100% 
 
Table 6.5 Prostate volume dose comparison 
 Reference case Plan 1 
 Abs Dose (Gy) Per Dose Abs Dose (Gy) Per Dose 
D100 72.24 50.51% 73.24 50.51% 
D90 155.67 107.36% 156.26 107.77% 
D80 173.48 119.64% 174.32 120.22% 
D50 215.25 148.45% 215.52 148.64% 
 
It is very clear from the tables above that the QA plan is very well in accordance 
with the reference plan. 
6.4.1.2 Isodose Line Comparison 
Because there are registration points on the images, it is easy to compare the 
position of these lines between the reference plan and the QA plan.  The comparison 
between the QA plan and reference plan show very good consistence. 
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6.4.2 VariSeed Internal Test Procedure 
There are altogether four types of seeds we are using at MBPCC.  They are. 
• I-125 (MED3631-A/M) NIST 1999 
• Pd-103 (MED 3633) NIST 2000 
• I-125 (STM1251) NIST 1999 
• Pd-103 (1031L) [NIST 1999] 
All of these four types of seeds were tested. 
6.4.2.1 Dose Calculation Verification Test Using a Dose Point 
The result is summarized as table 6.6. 
6.4.2.2 Dose Calculation Verification Test Using Isodose Contours  
The results (Figure 6.1) show that the number of isodose lines is reduced by one 
from image#1 to image #9 as expected. 
6.4.2.3 DVH and CVA Test Result  
Table 6.7 (a,b,c,d) are the test results for the four types of seeds respectively. 
From the DVH and CVA tests, 4 results were found off from the manual calculation by 
more than 5% and they are highlighted inside the tables.  Two of them are very close to 
the calculated result of equation 6.4 and the differences to the equation 6.5 are also only a 
little bit beyond 5% tolerance.  The other two differences were significantly higher, 
indicating the software has a miscalculation in these two cases. 
6.5 Discussion 
In the reference plan, the 100% and 150% isodose curves may not cover the 
“tumor” well.  But it really does not matter because we do not care about the treatment 
result.  As long as the reproducibility is verified, it is good enough for the QA purpose. 
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Table 6.6 Dose Calculation Verification Test Result Summaries 
a. I-125 (MED3631-A/M) NIST 1999 
 Anisotropy Constant Anisotropy Factor No Anisotropy Correction 
Distance 
in (cm) 
Manual 
Calculate 
Test 
Result 
Diff Manual 
Calculate
Test 
Result 
Diff Manual 
Calculate 
Test 
Result 
Diff
0.5 8177.82 8177.8 0.02 8041.52 8041.5 0.02 9086.47 9086.5 0.03
1.00 1921.48 1921.5 0.02 9930.98 9931.0 0.02 11221.45 11221.4 0.05
1.50 793.36 793.4 0.04 10694.37 10694.4 0.03 12102.96 12103.0 0.04
2.00 407.35 467.4 0.05 11077.74 11077.7 0.04 12555.58 12555.6 0.02
2.50 234.27 234.3 0.03 11308.49 11308.5 0.01 12815.88 12815.9 0.02
3.00 144.32 144.3 0.02 11456.98 11457.0 0.02 12976.24 12976.2 0.04
3.50 93.49 93.5 0.01 11549.38 11549.4 0.02 13080.11 13080.1 0.01
4.00 62.81 62.8 0.01 11608.91 11608.9 0.01 13149.90 13149.9 0.00
4.50 43.46 43.5 0.04 11652.10 11652.1 0.00 13198.19 13198.2 0.01
5.00 30.82 30.8 0.02 11684.15 11684.2 0.05 13232.44 13232.4 0.04
5.50 22.61 22.6 0.01 11707.89 11707.9 0.01 13257.57 13257.5 0.07
6.00 16.60 16.6 0.00 11725.49 11725.5 0.01 13276.01 13276.0 0.01
 
 
b.   Pd-103 (Med 3633) NIST 2000 
 Anisotropy Constant Anisotropy Factor No Anisotropy 
Correction 
Distance 
in (cm) 
Manual 
Calculate 
Test 
Result 
Diff Manual 
Calculate
Test 
Result 
Diff Manual 
Calculate 
Test 
Result 
Diff
0.5 2015.48 2015.5 0.02 2062.51 2062.5 0.01 2239.43 2239.4 0.03
1.00 2406.08 2406.1 0.02 2462.22 2462.2 0.02 434.00 434.0 0.00
1.50 2538.88 2538.9 0.02 2595.76 2595.8 0.04 147.56 147.6 0.04
2.00 2595.13 2595.1 0.03 2651.32 2651.3 0.02 62.50 62.5 0.00
2.50 2621.69 2621.7 0.01 2676.54 2676.5 0.04 29.51 29.5 0.01
3.00 2635.14 2635.1 0.04 2688.8 2688.8 0.00 14.95 14.9 0.05
3.50 2642.28 2642.3 0.02 2695.36 2695.4 0.04 7.94 7.9 0.04
4.00 2646.31 2646.3 0.01 2699.09 2699.1 0.01 4.48 4.5 0.02
4.50 2648.68 2648.7 0.02 2701.36 2701.4 0.04 2.64 2.6 0.04
5.00 2650.08 2650.1 0.02 2702.74 2702.7 0.04 1.55 1.6 0.05
5.50 2650.89 2650.9 0.01 2703.54 2703.5 0.04 0.90 0.9 0.00
6.00 2651.39 2651.4 0.01 2704.03 2704.0 0.03 0.55 0.6 0.05
(Table cont’d) 
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d. 103 (1031L) NIST 1999 
 Anisotropy Constant Anisotropy Factor No Anisotropy Correction 
Distance 
in (cm) 
Manual 
Calculate 
Test 
Result 
Diff Manual 
Calculate
Test 
Result 
Diff Manual 
Calculate 
Test 
Result 
Diff 
0.5 1772.07 1772.1 0.03 1795.86 1795.9 0.04 1982.18 1982.2 0.02 
1.00 364.92 364.9 0.02 367.78 367.8 0.02 408.19 408.2 0.01 
1.50 126.02 126.0 0.02 126.30 126.3 0.00 140.96 141.0 0.04 
2.00 53.74 53.7 0.04 53.55 53.6 0.05 60.11 60.1 0.01 
2.50 25.87 25.9 0.03 25.75 25.8 0.05 28.93 28.9 0.03 
3.00 13.26 13.3 0.04 13.18 13.2 0.02 14.83 14.8 0.03 
3.50 7.33 7.3 0.03 7.29 7.3 0.01 8.20 8.2 0.00 
4.00 4.11 4.1 0.01 4.09 4.1 0.01 4.59 4.6 0.01 
4.50 2.41 2.4 0.01 2.41 2.4 0.01 2.70 2.7 0.00 
5.00 1.43 1.4 0.03 1.43 1.4 0.03 1.60 1.6 0.00 
5.50 0.92 0.9 0.02 0.91 0.9 0.01 1.03 1.0 0.03 
6.00 0.54 0.5 0.04 0.54 0.5 0.04 0.60 0.6 0.00 
 
c.  I-125 (STM1251) NIST 1999 
 Anisotropy Constant Anisotropy Factor No Anisotropy Correction 
Distance 
in (cm) 
Manual 
Calculate 
Test 
Result 
Diff Manual 
Calculate
Test 
Result 
Diff Manual 
Calculate 
Test 
Result 
Diff
0.5 7822.33 7822.3 0.03 7830.64 7830.6 0.04 8312.78 8312.8 0.02
1.00 9715.44 9715.4 0.04 1895.12 1895.1 0.02 10324.59 10324.6 0.01
1.50 10503.82 10503.8 0.02 787.12 787.1 0.02 11162.40 11162.4 0.00
2.00 10908.95 10908.9 0.05 403.40 403.4 0.00 11592.93 11592.9 0.03
2.50 11142.79 11142.8 0.01 234.09 234.1 0.01 11841.43 11841.4 0.03
3.00 11288.14 11288.1 0.04 146.28 146.3 0.02 11995.89 11995.9 0.01
3.50 11382.72 11382.7 0.02 94.88 94.9 0.02 12096.40 12096.4 0.00
4.00 11446.61 11446.6 0.01 63.89 63.9 0.01 12144.30 12164.3 0.00
4.50 11491.02 11491.0 0.02 44.34 44.3 0.04 12211.49 12211.5 0.01
5.00 11522.45 11522.4 0.05 31.33 31.3 0.03 12244.89 12244.9 0.01
5.50 11545.26 11545.2 0.06 22.77 22.8 0.03 12269.13 12269.1 0.03
6.00 11561.77 11561.8 0.03 16.51 16.5 0.01 12286.68 12286.7 0.02
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Figure 6.1 Dose calculation verification result using isodose lines 
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Table 6.7 DVH and CVA Test Result Summary 
a. I-125 (MED3631-A/M) NIST 1999 
Radius in cm 4/3*πr3 Equation 6.5 Constant Difference Factor Difference
1.0 4.19 3.52 3.51 -0.28% 3.54 +0.57% 
1.5 14.14 13.04 13.07 -0.23% 13.07 +0.23% 
2.0 33.51 31.96 32.01 -0.16% 32.01 +0.16% 
2.5 65.45 63.43 63.38 +0.08% 62.38 -1.66% 
3.0 113.10 110.59 110.57 +0.02% 110.63 +0.04% 
 
b. Pd-103 (Med 3633) NIST 2000 
Radius in cm 4/3*πr3 Equation 6.5 Constant Difference Factor Difference
1.0 4.19 3.52 3.51 -0.30% 3.46 +1.7% 
1.5 14.14 13.04 13.19 +1.1% 12.85 +1.5% 
2.0 33.51 31.96 32.32 +1.1% 31.37 +1.8% 
2.5 65.45 63.43 64.52 +1.7% 67.67 -0.38% 
3.0 113.10 110.59 113.34 +0.25% 124.32 -12.4% 
 
c. I-125 (STM1251) NIST 1999 
Radius in cm 4/3*πr3 Equation 6.5 Constant Difference Factor Difference
1.0 4.19 3.52 3.51 +0.28% 3.54 +0.56% 
1.5 14.14 13.04 13.03 +0.08% 13.07 +0.23% 
2.0 33.51 31.96 32.01 -0.16% 31.95 -0.03% 
2.5 65.45 63.43 63.44 -0.02% 63.38 -0.08% 
3.0 113.10 110.59 110.57 +0.02% 110.57 -0.02% 
 
d. Pd-103 (1031L) NIST 1999 
Radius in cm 4/3*πr3 Equation 6.5 Constant Difference Factor Difference
1.0 4.19 3.52 3.63 +3.1% 4.12 -17.0% 
1.5 14.14 13.04 13.13 +0.69% 13.72 -5.21% 
2.0 33.51 31.96 31.85 -0.35% 32.57 -1.91% 
2.5 65.45 63.43 63.13 -0.57% 65.80 -3.74% 
3.0 113.10 110.59 110.14 -0.41% 116.96 -5.76% 
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6.6 Conclusion 
The VariSeed 6.7 prostate treatment planning system accuracy can be verified by 
the reference plan comparison with reliability.  The dose calculation verification test, 
dose calculation verification test using isodose contours, DVH and CVA results test are 
good supplements to the QA procedures. 
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CHAPTER 7. PLATO-BRACHYTHERAPY TPS QA 
 
7.1 Introduction 
PLATO-Brachytherapy TPS is used as an HDR planning system at MBPCC.  It 
runs on Indigo and Indy workstations under the Silicon Graphics IRIX operating system, 
a Silicon Graphics implementation of UNIX.  PLATO-TPS can be used to make standard 
and non-standard treatment plans for microSelectron-HDR, microSelectron-PDR, 
Selectron-LDR/MDR and Selectron-HDR afterloaders. 
Stam (1998) did commissioning and evaluation of the PLATO-
BRACHYTHERAPY TPS about 5 years ago.  But after that, none of the TPS QA has 
been performed. 
Dose distribution calculation in PLATO is based on point dose calculations.  The 
calculation of an absorbed dose to a particular point begins at the level of the exposure 
rate distribution of a source.  Then it is converted to dose by f factor, which is called the 
roentgen to rad conversion factor.  After the attenuation and scatter correction, the total 
dose to a particular point is calculated by summing the contribution to a point from each 
dwell position of the source.  The calculation formula can be written as: 
 Total ∑
=
×××Γ×=
n
i
pipip TdMFAradD
1
2 )/()()(   (7.1) 
Where  
A is the activity of source (Ci),  
 Γ is gamma factor or exposure rate constant (R×cm2/Ci-sec),  
 T is time of exposure or dwell time (sec), d is distance from the source,  
 F is f factor,  
 M is Meisberger factor,   
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 n is the total number of dwell positions,  
 i denotes one dwell position.   
The isotope used in MBPCC HDR system is Ir-192.  It has a low average gamma 
ray energy of 0.38 MeV and a small half value layer (2.5 mm of lead).  Its half-life is 
74.02 days, which makes it necessary to be replaced every four months. 
7.2 Methodology 
7.2.1 Reference Case 
The basic idea of PLATO Brachytherapy Computer QA is still the same as 
Pinnacle3 QA.  It mainly tests the reproducibility of the system.  Initially, two reference 
treatment plans were established.  Whenever the source is changed or the treatment 
planning result is doubtful, the reference plans can be repeated, and the result is 
compared to the reference plan. 
7.2.1.1 Reference Plan Making 
One of the reference cases is vagina cylinder treatment planning.  The reference 
dose points are 5mm away from the outside of the cylinder. 
The other reference case is tandem and ring treatment planning.  There are four 
films (AP, Lateral, LAO and RAO) in this case.  In order to be able to repeat the plan, all 
the points and catheter positions were plotted on a graph paper with the same relative 
positions. 
7.2.1.2 QA Plan Making 
In QA plan making, the exact same treatment planning procedures were executed 
as in the reference plan.  It includes the same films, the same catheter positions, the same 
source positions, the same prescription and the same optimization method.  If the 
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treatment planning system has been working consistently, the only difference between the 
QA plan and reference plan would be the source decay factor or the source strength ratio. 
In addition, three 2-D plots (AP, lateral and transversal) were printed out with 
isodose lines.  Because these isodose lines are in the form of percentage, the plot should 
be exactly the same each time. 
7.2.2 Software Calculation Test 
Sometimes, the reference tests may show a difference beyond the tolerance for 
some reason.  It is probably because the catheter points and the reference points can’t be 
digitized perfectly in the same position each time.  But in order to verify if it is the true 
reason, the software calculation test is necessary.  This test does not include the step of 
digitizing the image.  Instead, it clears the source position, prescription, optimization 
method, and dose calculation in the reference plan first.  Following that, the same 
prescription, optimization method and dose calculation were added up or executed again.    
This test is not affected by the digitizer, so the tolerance recommended is more strictly at 
1%. 
7.2.3 Digitizer Test 
Since all of the Plato HDR treatment planning inputs are from the digitizer, QA 
for the digitizer is much more important compared to the Pinnacle3 digitizer QA.  Also 
because the digitizer is the most easily broken part of the PLATO planning system, it is 
tested monthly or quarterly depending on the number of HDR cases.  The test procedure 
is the same as the Pinnacle3 digitizer test. 
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7.2.4 Checksum Test 
Because Plato HDR TPS software is also installed in a Unix system, a checksum 
program can also be utilized.  The spot checking file signatures can further ensure the 
consistency of the software. 
7.2.5 Output Check 
For the HDR machine, monthly QA was set up to check the source position and 
source strength.  Also, every morning before the HDR procedure, a preplan QA is 
performed to check the working condition of the machine, such as source position 
verification, console interrupt, measured dwell time, etc. 
7.2.5 Verification Frequency 
Since there are not many HDR cases at MBPCC, the QA test can be performed 
every six months or whenever the source is replaced.  If it is for the later reason, our test 
doubly checks the accuracy of the new source strength input. 
7.3 Result and Analyses 
7.3.1 Tandem & Ring Case 
7.3.1.1 Dose Information 
Table 7.1 is the list of source time, dose on catheters and decay factor.  Initial 
dose rate was used for comparison and it was calculated by: 
Initial dose rate = Dose / (Absolute time x DF) x ( newsourceoldsource AA / )     (7.1) 
Where oldsourceA  is initial activity of the old source and 
 newsourceA  is initial activity of the new source. 
Initial dose rate should have the same value if the PLATO TPS is working 
consistently. 
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Table 7.1 Initial dose rate comparison in Tandem & Ring case 
 Abs time (sec) Dose Decay factor Initial dose rate 
Point Ref  QA  Ref QA Ref QA Ref QA 
Tandem 26.7 24.6 41.43 41.70 
Ring 44.5 41.0 
568.53 569.35 0.514 0.555 
24.86 25.02 
 
7.3.1.2 Point Coordinates 
The point coordinate comparison is illustrated in table 7.2. 
Table 7.2 Point Coordinate comparisons in Tandem & Ring case 
Point  X (mm) Y (mm) Z (mm) Dose (cGy) 
Ref Plan 6.3 64.4 22.7 83.72 
QA Plan 6.9 64.1 22.6 84.12 
 
Bladder 
Diff +9.5% -0.5% -0.4% +0.5% 
Ref Plan 37.2 78.5 56.5 41.23 
QA Plan 37.5 78.4 56.6 41.02 
 
Rectum 
Diff +0.8% -0.1% +0.2% -0.5% 
 
From the table above, it is found that the X coordinate of the bladder point is off 
by +9.5%.  But the absolute value difference is only 0.3mm, which can be negligible. 
7.3.2 Vagina Cylinder Case  
7.3.2.1 Dose Information 
In this case, the prescription dose is on the dose points with 17.5mm away from 
the catheter.  The point doses were compared first (Table 7.3), and then the treatment 
time calculation was checked (Table 7.4 and figure 7.1). 
From the comparison, it can be seen that most of the results are good to be within 
the tolerance except 5 absolute time comparisons in the Vagina Cylinder case.  However, 
the total treatment time comparison was the same.  In order to ensure the error is because 
the catheter points in the reference case and the QA plan were not digitized in the same 
exact point, the software calculation test was performed, and the comparison result is in 
table 7.6. 
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Table 7.3 Point dose comparison in Vagina Cylinder case 
 Dose  
Point Ref QA Difference 
1 445.90 443.24 -0.60% 
2 499.89 501.06 +0.23% 
3 521.24 528.87 +1.46% 
4 524.65 523.29 -0.26% 
5 518.54 506.19 -2.38% 
6 500.00 498.10 +0.38% 
7 485.67 497.89 +2.51% 
8 495.13 498.31 +0.64% 
9 511.85 507.02 -0.94% 
10 524.51 523.37 -0.22% 
11 524.62 527.65 +0.58% 
12 501.94 501.16 -0.16% 
13 445.76 443.84 -0.43% 
 
 
 
Table 7.4 Absolute time comparison after correction by decay factor 
 Abs time (sec) Decay factor Time after DF correction  
Point Ref  QA  Ref QA Ref QA Difference
1 69.1 67.9 0.514 0.490 35.517 33.271 -6.3% 
2 60.9 60.3 0.514 0.490 31.303 29.547 -5.6% 
3 48.0 48.7 0.514 0.490 24.672 23.863 -3.3% 
4 35.3 37.4 0.514 0.490 18.144 18.326 +1.0% 
5 26.3 29.0 0.514 0.490 13.518 14.21 +5.1% 
6 21.7 24.5 0.514 0.490 11.154 12.005 +7.6% 
7 20.9 23.2 0.514 0.490 10.743 11.368 +5.8% 
8 22.9 24.6 0.514 0.490 11.771 12.054 +2.4% 
9 28.0 29.3 0.514 0.490 14.392 14.357 -0.2% 
10 36.8 37.9 0.514 0.490 18.915 18.571 -1.8% 
11 48.8 49.7 0.514 0.490 25.083 24.353 -2.9% 
12 61.1 61.8 0.514 0.490 31.405 30.282 -3.6% 
13 69.0 69.6 0.514 0.490 35.466 34.104 -3.8% 
Total  548.8 563.9 0.514 0.490 282.08 276.31 -2.0% 
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Figure 7.1 Absolute time comparisons  
after correction of decay factor in Vagina Cylinder case 
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7.3.2.2 Point Coordinate 
Table 7.5 Point coordinate comparison in Vagina Cylinder case 
Point Plan X (mm) Y (mm) Z (mm) Dose (cGy) 
Ref Plan 20.8 19.2 -10.1 222.15 
QA Plan 20.8 19.8 -10.1 213.27 
 
Pt 1 
Diff 0.0% +3.1% 0.0% -4.0% 
Ref Plan -19.0 -20.8 20.1 268.28 
QA Plan -19.3 -20.6 20.0 266.27 
 
Pt 2 
Diff -1.6% +1.0% +0.5% +0.8% 
 
Table 7.6 Point dose comparison in software calculation test 
 Abs time (sec) Decay factor Time after DF correction  
Point Ref  QA  Ref QA Ref QA Difference
1 69.1 91.2 0.514 0.389 35.517 35.477 -0.11% 
2 60.9 80.3 0.514 0.389 31.303 31.237 -0.21% 
3 48.0 63.3 0.514 0.389 24.672 24.624 -0.20% 
4 35.3 46.6 0.514 0.389 18.144 18.127 -0.09% 
5 26.3 34.7 0.514 0.389 13.518 13.498 -0.15% 
6 21.7 28.7 0.514 0.389 11.154 11.164 +0.09% 
7 20.9 27.5 0.514 0.389 10.743 10.698 -0.42% 
8 22.9 30.2 0.514 0.389 11.771 11.748 -0.20% 
9 28.0 36.9 0.514 0.389 14.392 14.354 -0.26% 
10 36.8 48.6 0.514 0.389 18.915 18.905 -0.05% 
11 48.8 64.4 0.514 0.389 25.083 25.052 -0.13% 
12 61.1 80.6 0.514 0.389 31.405 31.353 -0.16% 
13 69.0 91.0 0.514 0.389 35.466 35.466 -0.19% 
Total  548.8 724.0 0.514 0.389 282.08 282.08 -0.16% 
 
 The result shows the software calculation is still correct.  The difference out of 
tolerance between the QA plan and the reference plan must have been caused by 
digitization. 
7.3.3 Digitizer Test 
Three squares (twelve points) were tested.  The result is demonstrated in table 7.7 
and it shows the digitizer is in good working conditions. 
7.4 Discussion 
The HDR treatment program data is transferred to the HDR machine by a 
program card.  Although our QA procedures check the treatment planning software and  
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Table 7.7 Digitizer test in PLATO Brachytherapy planning system (Unit: cm) 
Point Expected coordinate Reading from software Difference 
Point1 (-2.0, -2.0, 2.0) (-1.8, -2.5, 2.1) (0.2, -0.5, 0.1) 
Point2 (-2.0, -2.0, -2.0) (-1.8, -2.2, -1.9) (0.2, -0.2, 0.1) 
Point3 (2.0, 2.0, -2.0) (1.7, 1.8, -2.0) (-0.3, -0.2, 0.0) 
Point4 (2.0, 2.0, 2.0) (2.1, 1.9, 2.0) (0.1, -0.1, 0.0) 
Point5 (-10, -10, 10) (-9.9, -10.1, 10.0) (0.1, -0.1, 0.0) 
Point6 (-10, -10, -10) (-9.9, -10.3, -9.7) (0.1, -0.3, 0.3) 
Point7 (10, 10, -10) (9.8, 10.0, -10.3) (-0.2, 0.0, -0.3) 
Point8 (10, 10, 10) (10.0, 9.8, 10.2) (0.0, -0.2, -0.3) 
Point9 (-20, -20, 20) (-19.4, -20.5, 20.1) (0.6, -0.5, 0.1) 
Point10 (-20, -20, -20) (-19.4, -20.5, -20.0) (0.6, -0.5, 0.0) 
Point11 (20, 20, -20) (20.4, 19.6, -20.0) (0.4, -0.4, 0.0) 
Point12 (20, 20, 20) (20.4, 19.6, 20.1) (0.4, -0.6, 0.1) 
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HDR machine separately, no data transfer accuracy can be verified.  It would be of 
significance if a simple treatment program can be made in the software and sent to a 
program card.  Then run the plan on the HDR machine and test the source position and 
strength.  However, this procedure would take much more time. 
7.5 Conclusion 
By the reference plan comparison and frequent digitizer test, the PLATO HDR 
treatment planning system was efficiently checked.  The total test time is less than half an 
hour.  Until now, no significant error has been found and it is safe to say that the system 
is working with consistency. 
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CHAPTER 8. GLOBAL DISCUSSION  
8.1 Test of Whole Radiation Treatment Process 
In chapter 4, the integration of CT and Pinnacle3 was verified.  However, that is 
only a partition of the whole radiation treatment process.  It would be valuable if the QA 
test would start from CT and end up with the LINACS. 
A test was performed to test an IMRT plan on a 21EX(BR) machine.  A RANDO 
phantom was utilized to simulate the patient’s head and scanned in the CT-Simulator.  
Then an IMRT plan was transferred to the phantom images.  Some KODAK XV-2 films 
were sandwiched between RANDO phantom slices and the phantom was treated in 
21EX(BR) (Figure 8.1).  Finally those films were analyzed in RIT 113 software (RIT, 
Inc) and the measured dose profiles were compared to the ADAC calculation. 
There are two advantages that make this test better than the regular IMRT QA 
used currently at MBPCC. 
First, the RANDO phantom is inhomogeneous, which allows the actual dose 
distribution in heterogeneous materials to be checked.  The regular IMRT QA procedure 
at MBPCC utilizes two 30cm X 30cm X 10cm solid water phantoms.  It is always 
doubtful if the homogeneous dose calculation would fit the measurement as well in an 
inhomogeneous patient’s body. 
Secondly, this test starts from the CT-simulator, and simulates the entire patient 
treatment process.  Any systematic error would be caught easily.  For example, the 
RANDO phantom was moved from the CT scan location (B. B. marker aligns with the 
CT laser) to the LINACS position (B. B. marker align with the LINACS laser) and then 
changed to treatment position (Isocenter) according to the ADAC treatment plan report.  
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The CT laser and LINACS laser system may be easily checked independently, but their 
relative position could be off.  Our test can find out this kind of error. 
 
Figure 8.1 RANDO phantom in treatment room 
 
 The result is shown in figure 8.2. 
From the profiles comparison, it is easy to see that the results are good overall.  
However, in most central areas, the measurement does not fit for the calculation within 
the tolerance.  In our experiment, there are still two aspects that could be changed to 
improve the accuracy.  First, there are thousands of holes inside the RANDO phantom.  
This special geometry makes both the Pinnacle3 calculation and film measurement much 
more complicated.  Filling out these holes with plugs could definitely improve the 
measurement accuracy.  Another way is to let the RANDO phantom slices lie on each 
other when it is scanned and treated.  By this way, there won’t be an air crevice between 
the phantom slices, which affects the measurement, when the film is sandwiched in. 
8.2 Test from Treatment Planning Computers to the LINACS 
The regular IMRT QA procedure at MBPCC does check the accuracy from treatment 
planning computers to the LINACS.  However, IMRT can only be implemented in the  
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(a) LSObrain dose profile (vertical)     (b) LSObrain dose profile (Perpendicular) 
 
 
 
 
 
 
 
 
 
 
 
(c) Vertex dose profile (Perpendicular)  (d) Vertex dose profile (Vertical) 
 
 
 
 
 
 
 
 
 
 
(e) RSO dose profile (Perpendicular)   (f) RSO dose profile (Vertical) 
 
 
 
 
 
(g) Composite dose profile (Perpendicular)  (h) Composite dose profile (Vertical) 
Figure 8.2 Test result of whole treatment process. (The dotted line and solid line are 
calculation and measurement respectively) 
   
 
90
21EX(BR) and 21EX(COV).  A similar way can be used for 2100C, 2000CR(Ham) and 
600C.  Instead of shooting an IMRT plan on the KODAK XV-2 film, a 3-D conformal 
treatment plan was imposed on the film.  This plan includes wedges and blocks.  The 
other procedures are the same as a regular IMRT plan:  the dose distribution in a plane 
was achieved from ADAC; shoot film sandwiched between solid water blocks; and 
analyze them by RIT software. 
In this test, the dose accuracy, dose distribution symmetry, wedge factor, tray 
factor, the position of blocks in the mount and a lot of other characters can be verified at 
the same time.  Our result is shown in figure 8.3. 
The result shows measurements and calculations fit better to each other in 
PA_boost field.  But in right boost field, the difference is as large as 10%. 
One of the problems in the experiment above is that the film analysis has a pretty 
high uncertainty compared to other dosimetry tools.  A better way is to put a TLD inside 
the RANDO phantom holes or use the gel dosimetry to measure the dose distribution 
directly.  But these two methods are too expensive to be used in a clinic. 
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(a) PA_boost dose profile (Vertical)      (b) PA_boost dose profile (Perpendicular) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) RT_boost dose profile (Vertical)      (d) RT_boost dose profile (Perpendicular) 
 
Figure 8.3 Test result from treatment planning computers to the LINACS 
(The dotted line and solid line are calculation and measurement respectively) 
 
 
   
 
92
CHAPTER 9. GLOBAL CONCLUSION 
QA procedures for all of the treatment planning systems at MBPCC were 
established based on the idea of simulating the actual patient treatment process.  They are 
fast and effective, but not perfect.  There are still many other QA tests that could be 
performed, and much more characteristics of the TPS could be checked.  However, it 
would make the whole TPS QA too time consuming and inefficient for clinical use.  It 
should be understood that all possible sources of error can never be tested. 
In the experiment from July to September, our test results show all of the 
treatment planning systems at MBPCC worked well.  Although no large errors have been 
found yet, the QA should not be taken for granted.  Quality assurance for treatment 
planning systems is a very extensive process.  It is an evolving subject that keeps 
changing with improvements in treatment planning computers.  MBPCC medical 
physicists should review the latest development and keep up with improvements in QA 
testing. 
   
 
93
REFERENCES 
1. Fraass B. Doppke K, Hunt M, Kutcher G, Starkschall G, Stern R, Van Dyke J. 
AAPM Radiation Therapy Committee Task Group 53: quality assurance fro 
clinical radiotherapy treatment planning.  Med. Phys. 1998; 25: 1773-1829. 
 
2. G. Kutcher et al., “Comprehensive QA for radiation oncology: Report of AAPM 
Radiation Therapy Committee Task Group 40,” Med. Phys. 21, 581-618 (1994). 
 
3. Ten Haken, R.K., Fraass, B.A. (1996).  Quality assurance in 3D treatment 
planning.  Front. Radiat. Ther. Oncol. 29: 104-114 
 
4. Frass, B.A (1996).  Quality assurance for 3-D treatment planning.  In: Mackie, 
T.R., Palta J.R., eds. Teletherapy: Present and Future. Madison WI: Advanced 
Medical Publishing: 253-318.  
 
5. Dahlin, H.; Lamm, I. L.; Landberg, T.; Levernes, S.; Ulso, N. User requirements 
on CT based computerized dose planning systems in radiotherapy. Acta Radiol. 
Oncol. 22: 398-415; 1983. 
 
6. Bruce Curran, George Starkschall: “A program for quality assurance of dose 
planning computers”, in Quality Assurance in Radiotherapy Physics, proceedings 
of an American College of Medical Physics Symposium edited by George 
Starkschall and John Horton (Medical Physics Publishing, Madison, WI 1991), pp 
207-228. 
 
7. ICRU: ICRU Report 29, “Dose specification for reporting external beam therapy 
with photons and electrons,” Bethesda, MD, International Committee on 
Radiation Units and Measurements, 1978. 
 
8. George Starkschall, Roy E. Steadham, Jr., Richard A. Popple, Salahuddin Ahmad, 
and Isaac I. Rosen: Beam-commissioning methodology for a three dimensional 
convolution/superposition photon dose algorithm. Journal of Applied Clinical 
Medical Physics, 2000, 1; 8-27. 
 
9. J. Van Dyk, R. Barnett, J. Cygler, and P. Shragg, (1993) “Commissioning and 
quality assurance of treatment planning computers,” Int. J. Radiat. Oncol., Biol., 
Phys. 26, 261-273. 
 
10. T. R. Mackie, J. W. Scrimger, and K. K. Battista, “ A convolution method of 
calculation dose for 15-MV x-rays,” Med. Phys. 12, 188-196 (1985). 
 
11. An ADAC Pinnacle3 Physics Guide, ADAC Laboratories, Milpitas, California, 
2001. 
 
   
 
94
12. AAPM Report # 55, “Radiation Treatment Planning Dosimetry Verification, 
Radiation Therapy Committee Task Group #23,” edited by D. Miller (American 
Institute of Physics, College Park, MD, 1995). 
 
13. Hogstrom, K. R, Millers, M.D., and Almond, P.R. 1981.  Electron beam dose 
calculations. Physics of Medicine and Biology 26: 445-459. 
 
14. M. L. Kessler, R. K. Ten Haken, B. A. Frass, and D. L. McShan, “Expanding the 
use and effectiveness of dose-volume histograms for 3D treatment planning, I. 
Integration of 3-D dose-display,” Int. J. Radiat. Oncol., Biol., Phys. 29, 1125-
1131 (1994). 
 
15. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. 
Meigooni, “Dosimetry of interstitial brachytherapy sources: Recommendations of 
the AAPM Radiation Therapy Committee Task Group No. 43, “ Med. Phys. 22, 
209-234 (1995).  
 
16. K. P. McGee, and I. J. Das: Commissioning, Acceptance testing, & quality 
assurance of a CT simulator (2000), Shirish Jani, eds, CT Simulation for 
Radiotherapy, Medical Physics Publishing: 5-23.   
 
17. Nagata Y, Nishidai T. Abe M, Takahashi M, Yukawa, Nohara H, Yamaoka N, 
Saida T, Ishihara H, Kubo Y, Ohta H, Inamura K. CT simulator: A new treatment 
planning system for radiotherapy. Int J Rad Oncol Biol Phys 1990; 13-176. 
 
18. Nishidai T Nagato Y, Takahashi M, Abe M, Yamaoka N, Ishihara H, Kubo Y, 
Ohta H, Kazusa C. CT simulator: a new 3-D planning and simulating system for 
radiotherapy: part I. Description of system. Int J Rad Oncol Biol Phys 1989; 18: 
499-504. 
 
19. Sherouse GW, Novins K, Chaney E. Computation of digitally reconstructed 
radiography for use in radiotherapy treatment design. Int J Rad Oncol Biol Phys 
1990; 18: 651-658. 
 
20. Lawrence Rothenberg: Quality Control in CT, 2002 AAPM Annual Meeting. 
 
21. A VariSeed User Guide for version 6.7, Varian Medical System, Inc, California, 
2000. 
 
22. A Nucletron Corporation User Manual.  New Implementations for Version 10.11.  
Nucletron Corporation, Columbia, Maryland, 1995, pp. 4-7. 
 
23. Angela Stam: Commissioning and evaluation of the PLATO-Brachytherapy 
planning system.  Master thesis, 1998. 
 
   
 
95
24. Ravinder Nath, Lowell L. Anderson, Jerome A. Meli, Arthur J.Olch, Judith Anne 
Stitt, Jeffrey F. Williamson: AAPM Radiation Therapy Committee Task Group 
56: Code of practice for brachytherapy physics. Med. Phys. 1997; 25: 1557-1598. 
 
 
 
 
 
 
   
 
96
VITA 
 Junqing Wu was born in Guixi city of Jiangxi Province, People’s Republic of 
China.  He received a Bachelor of Science degree from Peking University in July 2000.  
He began his graduate work in the Department of Physics and Astronomy in the Fall of 
2000.  Junqing will receive a Master of Science degree from the Department of Physics 
and Astronomy at Louisiana State University in the Fall of 2002. 
